EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 63

Results Generated From:
Embase <1980 to 2024 Week 40>
Embase Weekly Updates (updates since 2024-09-27)

<1>
Accession Number
2034766188
Title
Outcomes of definite vs probable/presumed cardiac sarcoidosis: a
systematic review and meta-analysis.
Source
Current Problems in Cardiology. 49(12) (no pagination), 2024. Article
Number: 102820. Date of Publication: December 2024.
Author
Ahmed R.; Ahsan A.; Ahmed M.; Dragon M.; Caballero R.R.H.; Tabassum S.;
Jain H.; Ullah M.Z.S.; Dey D.; Ramphul K.; Collins P.; Chahal A.; Kouranos
V.; Paray N.B.; Sharma R.
Institution
(Ahmed, Collins, Kouranos, Sharma) Royal Brompton Hospital, part of Guy's
and St Thomas' NHS Foundation Trust, London, United Kingdom
(Ahmed, Collins, Kouranos, Sharma) National Heart and Lung Institute,
Imperial College London, United Kingdom
(Ahsan) Foundation University School of Health Sciences, Islamabad,
Pakistan
(Ahmed) Rawalpindi Medical University, Rawalpindi, Pakistan
(Dragon) Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(Caballero) Department of Cardiology, Hospital Universitario Marques de
Valdecilla, Santander, Spain
(Tabassum) King Edward Medical University, Lahore, Pakistan
(Jain) All India Institute of Medical Sciences, Jodhpur, India
(Ullah) University Hospitals Birmingham NHS Foundation Trust, Birmingham,
United Kingdom
(Dey) Department of Internal Medicine, Medical College, Kolkata, India
(Ramphul) Independent Researcher, Triolet, Mauritius
(Chahal) Department of Cardiology, Barts Heart Centre, London, United
Kingdom
(Chahal) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
(Chahal) Center for Inherited Cardiovascular Diseases, Department of
Cardiology, Wellspan Health, York, PA 17403, United States
(Paray) Royal Devon University Healthcare NHS Foundation Trust, Exeter,
United Kingdom
(Sharma) King's College London, London, United Kingdom
Publisher
Elsevier Inc.
Abstract
Background: Diagnosing cardiac sarcoidosis (CS), which can be associated
with arrhythmias and heart failure, remains challenging despite multiple
advances over time. The 2014 Heart Rhythm Society (HRS) consensus
statement recommends an endomyocardial biopsy (EMB) to establish a
definite diagnosis of CS. In the absence of a positive EMB, a diagnosis of
probable or presumed CS is made on the basis of clinical and imaging
criteria. <br/>Objective(s): To investigate whether there is any
difference in outcomes between definite vs probable/presumed CS.
<br/>Method(s): PubMed/MEDLINE, Embase, and the Cochrane Library databases
were searched for relevant studies published after 2014. Risk ratios (RR)
with 95% confidence intervals (CI) were calculated using the random
effects model and presented in forest plots. <br/>Result(s): 6 studies
involving 2,204 patients were identified. The cohort had a mean age of
56.8 years (SD: +/-13.6 years). The median duration of follow-up was 40.5
months. No statistically significant difference was observed between
definite and probable/presumed CS for reduced risk of the composite
endpoint (RR: 1.80, 95% CI: 0.93 to 3.49), and all-cause death (RR: 1.01,
95% CI: 0.48 to 2.10). <br/>Conclusion(s): This meta-analysis demonstrated
the equivalence of clinical course and prognosis between definite and
probable/presumed CS. This highlights the importance of a
multi-disciplinary approach to CS care and emphasizes that histological
confirmation should not be a prerequisite to diagnose or manage this
condition.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<2>
Accession Number
2034771641
Title
The use of tranexamic acid in paediatric adenotonsillectomy - A systematic
review and meta-analysis.
Source
International Journal of Pediatric Otorhinolaryngology. 186 (no
pagination), 2024. Article Number: 112110. Date of Publication: November
2024.
Author
Hannigan A.; Bumbak P.; Brennan-Jones C.G.; Hintze J.
Institution
(Hannigan, Bumbak, Brennan-Jones) Department of Otolaryngology, Perth
Children's Hospital, Perth, WA, Australia
(Brennan-Jones) Telethon Kids Institute, The University of Western
Australia, Australia
(Brennan-Jones) Faculty of Health Sciences, Curtin University, WA,
Australia
(Hintze) Department of Otolaryngology - Head and Neck Surgery, Mayo
Clinic, United States
Publisher
Elsevier Ireland Ltd
Abstract
Background: Tonsillectomy and adenoidectomy (AT) are two of the most
commonly performed ENT procedures in children, with over 500,000 cases
performed annually in the United States. Whilst generally considered a
safe and well-tolerated operation, it is not without its risks and
complications including pain, nausea, anorexia and most importantly
bleeding and post-tonsillectomy haemorrhage (PTH). Whilst tranexamic acid
(TXA) has a proven benefit in reducing bleeding and transfusion
requirements in patients undergoing trauma, spinal and cardiac surgery;
the effectiveness, timing and safety of its application in paediatric
tonsillectomy has not yet been established. Aims, objectives &
significance: To date, there has been no published systematic review of
the literature specifically looking at paediatric patients undergoing AT,
despite a massive surge in popularity of the use of TXA perioperatively.
The aim of this study is therefore to systematically review the current
literature and collate evidence regarding the efficacy and safety of using
TXA to reduce bleeding in children undergoing tonsillectomy and/or
adenoidectomy. <br/>Method(s): A structured search of bibliographic
databases (MEDLINE, EMBASE, PubMed, CINAHL, Cochrane CENTRAL) was
undertaken to retrieve randomised controlled trials, non-randomised
case-control studies and ongoing clinical trials that describe the use of
TXA in paediatric patients undergoing AT. The following search terms (and
their variations) were used as both medical subject headings (MeSH terms)
and text words: tranexamic acid, bleeding, tonsillectomy, adenoidectomy,
paediatrics. To ensure that all relevant data was captured, the search did
not contain any restrictions on language or publication time. Data
extraction and risk of bias assessment was performed independently and in
duplicate. <br/>Result(s): This review identified and included a total of
eight studies (n = 1315). Five studies reported on the intravenous use of
TXA (n = 531) whilst three studies reported on the topical use of TXA (n =
784), and these were analysed separately. The intravenous use of TXA did
not reduce intraoperative blood loss significantly (95 % CI: -0.1 to 0.33
p = 0.28) and there was not enough information to analyse the effect on
PTH in these studies. Topical TXA led to a significant reduction in both
intraoperative blood loss (95 % CI 0.11 to 5.31, p = 0.04) and post
operative bleeding rates (RR 0.04, 95 % CI 0.01 to 0.08, P = 0.02).
<br/>Conclusion(s): The results of this systematic review and
meta-analysis suggest that TXA administered via the intravenous route does
not reduce perioperative bleeding associated with AT in paediatric
patients. However, when topical TXA is used intraoperatively at the
surgical site in paediatric patients undergoing adenoidectomy alone, there
was a significant reduction in both intraoperative blood loss and post
operative bleeding. TXA appears to be a safe and well-tolerated drug in
the paediatric population with no adverse effects reported in this review.
Nevertheless, further large and well-designed randomised controlled trials
are needed to investigate the risks and benefits of TXA in paediatric AT
with a particular focus on its use topically and in association with newly
developed surgical equipment.<br/>Copyright &#xa9; 2024 Elsevier B.V.

<3>
Accession Number
2034781852
Title
The efficacy of magnesium sulphate in preventing laryngospasm in
paediatric patients undergoing general anaesthesia: A systematic review
and meta-analysis of randomised control trials.
Source
Anaesthesia Critical Care and Pain Medicine. 43(5) (no pagination), 2024.
Article Number: 101413. Date of Publication: October 2024.
Author
Rasheed M.A.; Memon D.; Jimenez C.K.; Zafar A.; Shiwani H.
Institution
(Rasheed) University of Galway, Galway, Ireland
(Memon) Great Ormond Street Hospital for Children, London, United Kingdom
(Jimenez, Zafar) Cork University Hospital, Cork, Ireland
(Shiwani) Manchester Royal Infirmary, Manchester, United Kingdom
Publisher
Elsevier Masson s.r.l.
Abstract
Background: Laryngospasm is sustained closure of the airways and can be a
life-threatening condition. Magnesium sulphate is postulated to reduce the
incidence of laryngospasm if administered peri-operatively. This
systematic review and meta-analysis was performed to assess the efficacy
of magnesium sulphate in preventing peri-operative laryngospasm in
paediatric patients undergoing non-cardiac surgery. <br/>Method(s): Four
databases and a trial registry were searched. Inclusion criteria were
paediatric patients undergoing general anaesthesia. Exclusion criteria
were patients who underwent cardiopulmonary bypass during surgery. The
intervention of interest was the peri-operative administration of
magnesium sulphate. The intervention was compared to either a placebo or
other pharmacological agent. The primary outcome was the incidence of
laryngospasm. A meta-analysis of all studies was performed. Sub-group
analysis was subsequently performed. <br/>Result(s): A total of 953
patients from 13 trials were included in this study. Nine RCTs
administered magnesium intravenously and 4 RCTs administered magnesium
locally. Laryngospasm rates were 6% lower in the magnesium group (OR 0.48
[95% CI 0.25-0.96], p = 0.04) compared to control in the pooled data.
Subgroup analysis showed laryngospasm rates were lower by 12.5% (Odds
Ratio 0.26 [CI 0.09-0.76], p = 0.01) in the local magnesium group.
Subgroup analysis of studies that only administered intravenous magnesium
did not show a statistically significant difference in the incidence of
laryngospasm (OR 0.73 [95% CI 0.33-1.63], p = 0.44). <br/>Conclusion(s):
This review shows a potential role for magnesium in the prevention of
laryngospasm in paediatric patients undergoing general anaesthesia. There
is a correlation between local administration of magnesium and reduction
in laryngospasm rates. Further studies are required to assess the efficacy
of intravenous magnesium in prevention of laryngospasm. Registration:
Prospective Register of Systematic Reviews (PROSPERO); PROSPERO ID
CRD42022307868
(https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022307868)
.<br/>Copyright &#xa9; 2024 Societe francaise d'anesthesie et de
reanimation (Sfar)

<4>
Accession Number
2034736105
Title
Variation in the Branching Pattern of the Coronary Artery: A Systematic
Review on Anatomical Branching Variation.
Source
Research in Cardiovascular Medicine. 13(3) (pp 67-74), 2024. Date of
Publication: 2024.
Author
Vidhale D.; Hiware S.; Anjum S.; Ahmad A.; Bayer S.B.; Hardaha S.R.; Begum
Y.; Ismail E.E.; Ali M.T.; Saffar R.A.M.A.
Institution
(Vidhale) Department of Anatomy, Dr. Panjabrao Deshmukh Alias Memorial
Medical College, Maharashtra, Amravati, India
(Hiware) Department of Anatomy, College of Medicine, Imam Abdulrahman Bin
Faisal University, Dammam, Saudi Arabia
(Anjum) Department of Anatomy, College of Medicine, Talibah University, Al
Madinah Al Munawwarah, Saudi Arabia
(Ahmad) Department of Biochemistry, Imam Abdulrahman Bin Faisal
University, Dammam, Saudi Arabia
(Bayer, Begum, Ismail, Saffar) Department of Anatomy, Imam Abdulrahman Bin
Faisal University, Dammam, Saudi Arabia
(Hardaha) Department of Physiotherapy, Singhania University, Rajasthan,
Jhunjhunu, India
(Ali) Department of Pharmacology, Imam Abdulrahman Bin Faisal University,
Dammam, Saudi Arabia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: The coronary arteries, being the major vascular channels, are
known to affect the complete circulatory system and hemodynamics of the
body. However, as a matter of fact, the coronary arteries are known to
have many anatomical and developmental variations along all the
morphological aspects, which include location of orifices, various routes
that the artery and its tributaries follow, and of course, the pattern of
branching of the main artery. The developmental anomalies in the arterial
structures result in abnormalities of arterial blood flow, hypoxia, and
other conditions which may lead to atherosclerosis of the coronary artery.
To the best of our knowledge, the current systematic review and
meta-analysis aim to assess the association between variations in the
branching pattern of the coronary artery. Moreover, we propose future
studies to assess the association and preventive strategies for clinicians
and various health-care workers. Methodology: We performed an electronic
search of PubMed, MEDLINE, Cochrane Central Register, EMBASE, Science
Citation Index, Web of Science, and Database of Abstracts of Reviews of
Effects, and various clinical tribulation registries till 2022. Two
independent reviewers extracted the data, and the present meta-analysis
was performed with the help of RevMan version 5.4. For the present
meta-analysis, we used 10-year database from 2012 to 2022. <br/>Result(s):
Appropriate data were fetched from studies that were included for the
meta-analysis, and the data were presented in tables for evaluation and
drawing of accurate results. A total of 904 articles were found after
searching all of the major medical databases. Thirteen more sources of
reference were included in the search. After primary screening, full text
articles of around 148 were analyzed, and among them, 114 were excluded
because those articles were in the category of #case series, reports, or
#letters to the editors, #animal studies or #irrelevant documents,
reporting duplicate documents, or broadcasting a certain variant as
opposed to occurrence. After the complete screening and analysis of the
data were done, the final number of articles that were included in the
meta-analysis was 29 (n = 29). <br/>Conclusion(s): The present
meta-analysis is an attempt to review and analyze the recent literature
published on the variation in anatomy and developmental abnormalities of
the coronary arteries in the differing population across the geography of
the globe. The structural aspects of the coronary arteries, and not just
the lifestyle issues, are the ones which are associated with coronary
artery disease (CAD), a major cause of mortality in the population.
However, the anatomical factors are not attending limelight as other
obesity- or age-related issues for the same. Hence, the present review
aimed to deliver a thorough understanding of the most predominant
branching pattern of the coronary artery seen among Asian population. This
study will be beneficial to cardiologists and radiologists when performing
various treatments such as coronary angiograms, coronary angioplasty,
bypass grafting, and other medical procedures and can also lead to
prevention of the CAD.<br/>Copyright &#xa9; 2024 Research in
Cardiovascular Medicine.

<5>
Accession Number
2034695400
Title
Comparison of routine del Nido cardioplegia vs two types of modified del
Nido cardioplegias for myocardial protection among patients undergoing
coronary artery bypass grafting (CABG) surgeries: A randomized
double-blind clinical trial.
Source
Journal of Extra-Corporeal Technology. 56(3) (pp 84-93), 2024. Date of
Publication: 01 Sep 2024.
Author
Ali B.; Butt S.P.; Nour M.G.; Khosravi M.B.; Asmarian N.; Shoul A.R.;
Kumar A.; Darr U.; Bhatnagar G.
Institution
(Ali) Student Research Committee of Shiraz University of Medical Sciences,
PO BOX 71348-14336, Shiraz, Iran, Islamic Republic of
(Butt, Kumar, Darr, Bhatnagar) Heart Vascular and Thoracic Institute,
Cleveland Clinic Abu Dhabi, PO BOX 112412, United Arab Emirates
(Nour) Department of Surgery, Section of Cardiac Surgery, Shiraz
University of Medical Sciences, PO BOX 71348-14336, Shiraz, Iran, Islamic
Republic of
(Khosravi, Asmarian) Anesthesiology and Critical Care Research Center,
Shiraz University of Medical Sciences, PO BOX 71348-14336, Shiraz, Iran,
Islamic Republic of
(Shoul) Department of Perfusion, Division of Anesthesiology and Critical
Care Research Center, Shiraz University of Medical Sciences, PO BOX
71348-14336, Shiraz, Iran, Islamic Republic of
Publisher
EDP Sciences
Abstract
Background: The del Nido cardioplegia solution is a widely used method for
myocardial protection in various settings. However, there is limited
evidence of its effectiveness in adult cardiac surgery, and the baseline
solution, Plasma Lyte A, is not readily available, leading to the use of
alternative baseline solutions. This study aims to investigate the
effectiveness of routine del Nido cardioplegia in adult cardiac surgery
and the impact of different baseline solutions on myocardial protection
and other perioperative outcomes. <br/>Method(s): This study was a
prospective, double-blind randomized parallel group clinical trial
conducted at a single tertiary care hospital in Iran. A total of 187 adult
patients were evaluated for eligibility, of which 120 met the inclusion
criteria for elective isolated CABG surgery. The patients were randomly
assigned to three groups, with each group consisting of 40 patients. The
control group received a normal saline-based routine del Nido
cardioplegia, Intervention Group A received Ringer lactate-based del Nido
cardioplegia, and Intervention Group B received plain Ringer-based del
Nido cardioplegia. The levels of Creatine Kinase-MB (CK-MB), Troponin T,
Troponin I, and lactate were primarily assessed at four different times:
after anesthesia induction (Baseline), 2 h, 12 h, and 24 h.
<br/>Result(s): Preoperative demographic and clinical characteristics were
the same among groups with insignificant differences (p > 0.05). There was
no significant difference among groups based on CK-MB, Troponin T,
Troponin I, and lactate levels (p = 0.078, 0.143, 0.311, and 0.129
respectively). However, there was a significant difference in the time
effect of Troponin T and Lactate (p = 0.034, p = <0.001).
<br/>Conclusion(s): Normal saline, Ringer lactate, and plain Ringer
provide comparable myocardial protection in adult-isolated CABG surgery
with modified del Nido cardioplegia. Larger studies are needed to identify
the best alternative to Plasma Lyte A while maintaining del Nido
cardioplegia as the control.<br/>Copyright &#xa9; 2024 EDP Sciences. All
rights reserved.

<6>
Accession Number
2031142143
Title
EXPLORING THE EFFICACY AND THERAPEUTIC POTENTIAL OF MESENCHYMAL STEM
CELL-DERIVED EXOSOMES FOR THE TREATMENT OF ANDROGENIC ALOPECIA.
Source
Journal of Population Therapeutics and Clinical Pharmacology. 31(8) (pp
1752-1760), 2024. Date of Publication: 01 Aug 2024.
Author
Nadeem H.; Mahrukh; Farhan F.; Mahmood A.R.; Munam A.U.; Gul M.; Zafar S.;
Haleema S.
Institution
(Nadeem) Facial Aesthetician, JMDC, Pakistan
(Mahrukh) Bin Khalid Hospital and Skin Care Complex, Burewala, Pakistan
(Farhan) Department of Oral Pathology, Rawalpindi Institute of Health
Sciences, Islamabad, Pakistan
(Mahmood) Akhtar Saeed Medical and Dental College, Lahore, Pakistan
(Munam, Zafar, Haleema) Continental Medical College, Lahore, Pakistan
(Gul) Cantonment Board, Medical Centre Jhelum, Pakistan
Publisher
Codon Publications
Abstract
Introduction: Androgenic alopecia, a form of hair loss driven by genetic
predisposition and hormonal influences, is the most common cause of hair
thinning and baldness in both men and women. <br/>Objective(s): The main
objective of the study is to find the efficacy and therapeutic potential
of mesenchymal stem cell-derived exosomes for the treatment of androgenic
alopecia. Methodology of the study: This Randomized control trial was
conducted at different aesthetics clinics and patients provide the data
during 2023 to June 2024. A total of 85 patients, aged between 18 and 55
years, with clinically diagnosed androgenic alopecia (Norwood-Hamilton
classification II-V for men, and Ludwig classification I-II for women)
were enrolled. Participants with stable hair loss patterns for at least
one year and had not undergone any hair loss treatments (such as minoxidil
or finasteride) in the six months were included in the study.
<br/>Result(s): The treatment group showed a significant increase in hair
density, with a mean increase of 35 hairs/cm2 over 12 weeks, compared to
their baseline density of 100 hairs/cm2. This change is statistically
significant, as indicated by a p-value of 0.001. In contrast, the placebo
group exhibited a negligible increase in hair density, with a mean
increase of just 3 hairs/cm2, suggesting the effectiveness of the
treatment over the placebo. <br/>Conclusion(s): It is concluded that
mesenchymal stem cell-derived exosomes significantly enhance hair density
and thickness in patients with androgenic alopecia, offering a promising
and well-tolerated treatment option.<br/>Copyright &#xa9; 2024, Codon
Publications. All rights reserved.

<7>
Accession Number
2030763540
Title
Clinical and cost-effectiveness of left ventricular assist devices as
destination therapy for advanced heart failure: systematic review and
economic evaluation.
Source
Health Technology Assessment. 28(38) (pp v-104), 2024. Date of
Publication: 2024.
Author
Beese S.; Avsar T.S.; Price M.; Quinn D.; Lim H.S.; Dretzke J.; Ogwulu
C.O.; Barton P.; Jackson L.; Moore D.
Institution
(Beese, Avsar, Price, Dretzke, Ogwulu, Barton, Jackson, Moore) Institute
of Applied Health Research, University of Birmingham, Birmingham, United
Kingdom
(Avsar) Institute of Epidemiology and Health, University College London,
London, United Kingdom
(Quinn, Lim) Cardiology, University Hospitals Birmingham NHS Foundation
Trust, Birmingham, United Kingdom
Publisher
NIHR Journals Library
Abstract
Background: Selected patients with advanced heart failure ineligible for
heart transplantation could benefit from left ventricular assist device
therapy as 'destination therapy'. There is evidence of the efficacy of
destination therapy; however, it is not currently commissioned within the
United Kingdom National Health Service due to the lack of economic
evidence. <br/>Objective(s): What is the clinical and cost-effectiveness
of a left ventricular assist device compared to medical management for
patients with advanced heart failure ineligible for heart transplantation
(destination therapy)? Methods: A systematic review of evidence on the
clinical and cost-effectiveness of left ventricular assist devices as
destination therapy was undertaken including, where feasible, a network
meta-analysis to provide an indirect estimate of the relative
effectiveness of currently available left ventricular assist devices
compared to medical management. For the systematic reviews, data sources
searched (up to 11 January 2022) were Cochrane CENTRAL, MEDLINE and EMBASE
via Ovid for primary studies, and Epistemonikos and Cochrane Database of
Systematic Reviews for relevant systematic reviews. Trial registers were
also searched, along with data and reports from intervention-specific
registries. Economic studies were identified in EconLit, CEA registry and
the NHS Economic Evaluation Database (NHS EED). The searches were
supplemented by checking reference lists of included studies. An economic
model (Markov) was developed to estimate the cost-effectiveness of left
ventricular assist devices compared to medical management from the United
Kingdom National Health Service/personal social service perspective.
Deterministic and probabilistic sensitivity analyses were conducted to
explore uncertainties. Where possible, all analyses focused on the only
currently available left ventricular assist device (HeartMate 3TM, Abbott,
Chicago, IL, USA) in the United Kingdom. <br/>Result(s): The clinical
effectiveness review included 134 studies (240 articles). There were no
studies directly comparing HeartMate 3 and medical management (a
randomised trial is ongoing). The currently available left ventricular
assist device improves patient survival and reduces stroke rates and
complications compared to earlier devices and relative to medical
management. For example, survival at 24 months is 77% with the HeartMate 3
device compared to 59% with the HeartMate II (MOMENTUM 3 trial). An
indirect comparison demonstrated a reduction in mortality compared to
medical management [relative risk of death 0.25 (95% confidence interval
0.13 to 0.47); 24 months; this study]. The cost-effectiveness review
included 5 cost analyses and 14 economic evaluations covering different
generations of devices and with different perspectives. The reported
incremental costs per qualityadjusted life-year gained compared to medical
management were lower for later generations of devices [as low as 46,207
(2019 prices; United Kingdom perspective; time horizon at least 5 years)].
The economic evaluation used different approaches to obtain the relative
effects of current left ventricular assist devices compared to medical
management from the United Kingdom National Health Service/personal social
service perspective. All gave similar incremental cost-effectiveness
ratios of 53,496-58,244 per quality-adjusted life-year gained - lifetime
horizon. Model outputs were sensitive to parameter estimates relating to
medical management. The findings did not materially differ on exploratory
subgroup analyses based on the severity of heart failure.
<br/>Limitation(s): There was no direct evidence comparing the clinical
effectiveness of HeartMate 3 to medical management. Indirect comparisons
made were based on limited data from heterogeneous studies regarding the
severity of heart failure (Interagency Registry for Mechanically Assisted
Circulatory Support score distribution) and possible for survival only.
Furthermore, the cost of medical management of advanced heart failure in
the United Kingdom is not clear. <br/>Conclusion(s): Using
cost-effectiveness criteria applied in the United Kingdom, left
ventricular assist devices compared to medical management for patients
with advanced heart failure ineligible for heart transplant may not be
cost-effective. When available, data from the ongoing evaluation of
HeartMate 3 compared to medical management can be used to update
cost-effectiveness estimates. An audit of the costs of medical management
in the United Kingdom is required to further decrease uncertainty in the
economic evaluation.<br/>Copyright &#xa9; 2024 Beese et al.

<8>
Accession Number
2031601122
Title
Contractile Effects of Semaglutide in the Human Atrium.
Source
Pharmaceutics. 16(9) (no pagination), 2024. Article Number: 1139. Date of
Publication: September 2024.
Author
Neumann J.; Hadova K.; Klimas J.; Hofmann B.; Gergs U.
Institution
(Neumann, Gergs) Institute for Pharmacology and Toxicology, Medical
Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Strase 4,
Halle (Saale) D-06112, Germany
(Hadova, Klimas) Department of Pharmacology and Toxicology, Faculty of
Pharmacy, Comenius University, Bratislava SK-83232, Slovakia
(Hofmann) Department of Cardiac Surgery, Mid-German Heart Center,
University Hospital Halle, Ernst-Grube-Strase 40, Halle (Saale) D-06097,
Germany
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R
agonists are used to treat type 2 diabetes and obesity. It is currently
unknown whether semaglutide can directly increase force of contraction
(FOC) in the human heart. We tested the hypothesis that semaglutide might
increase the FOC in the isolated human atrium. To this end, we conducted
contraction experiments in isolated human right atrial muscle preparations
(HAP). HAP were obtained during open-heart surgery. We detected a
concentration- and time-dependent positive inotropic effect (PIE) of
semaglutide in HAP. These PIEs were accompanied by increases in the rates
of tension development and tension relaxation and a reduction in muscle
relaxation time. The PIE of semaglutide in HAP was attenuated by H89, an
inhibitor of the cyclic AMP-dependent protein kinase and by ryanodine, an
inhibitor of sarcoplasmic Ca²⁺ release. Semaglutide up to 100
nM failed to exert a PIE in isolated electrically paced (1 Hz) wild-type
mouse left atrial preparations studied for comparison. Our data suggest
that semaglutide can increase the FOC in the atria of patients at
therapeutic drug concentrations.<br/>Copyright &#xa9; 2024 by the authors.

<9>
Accession Number
2031592962
Title
Use of Ketamine in Patients with Multifactorial Neuropathic Pain: A
Systematic Review and Meta-Analysis.
Source
Pharmaceuticals. 17(9) (no pagination), 2024. Article Number: 1165. Date
of Publication: September 2024.
Author
Bruna-Mejias A.; Baeza V.; Gamboa J.; Baez Flores B.; San Martin J.;
Astorga C.; Leyton J.; Nova-Baeza P.; Orellana-Donoso M.; Suazo-Santibanez
A.; Becerra-Farfan A.; Oyanedel-Amaro G.; Valenzuela-Fuenzalida J.J.
Institution
(Bruna-Mejias) Departamento de Ciencias y Geografia, Facultad de Ciencias
Naturales y Exactas, Universidad de Playa Ancha, Valparaiso 2360072, Chile
(Baeza, Gamboa, Baez Flores, San Martin, Leyton, Nova-Baeza,
Valenzuela-Fuenzalida) Departamento de Morfologia, Facultad de Medicina,
Universidad Andres Bello, Santiago 8420524, Chile
(Astorga, Orellana-Donoso) Faculty of Medicine and Science, Universidad
San Sebastian, Santiago 8420524, Chile
(Orellana-Donoso) Escuela de Medicina, Universidad Finis Terrae, Santiago
7501015, Chile
(Suazo-Santibanez) Faculty of Health and Social Sciences, Universidad de
las Americas, Santiago 8370040, Chile
(Becerra-Farfan) Escuela de Fonoaudiologia, Departamento de Ciencias
Quimica y Biologicas, Facultad de Ciencias de la Salud, Universidad
Bernardo O'Higgins, Santiago 8320000, Chile
(Oyanedel-Amaro) Facultad de Ciencias de la Salud, Universidad Autonoma de
Chile, Santiago 8910060, Chile
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Neuropathic pain (NP) is a heterogeneous group of conditions characterized
by the experience of a number of sensory disturbances including pain,
burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia,
and hyperalgesia. The above-mentioned sensations may occur in a specific
dermatome area or other delimited region of the body. The objective of
this review was to analyze the evidence for ketamine in multifactorial
neuropathic pain. The research group systematically searched the databases
MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of
Controlled Trials, the Cumulative Index to Nursing and Allied Health
Literature (Cinahl), and the Web of Science. The findings of this review
show that different forms of low doses of ketamine (LDK) do not present
statistically significant changes for any of the scales included. In this
study, the total symptom score [standardized mean difference (SMD) =
-3.59, confidence interval (CI) = -4.16 to -3.02, and p < 0.00001],
neuropathy impairment score (SMD = -1.42, CI = -3.68 to 0.84, and p =
0.22), and neuropathy symptom checklist (SMD = -0.09, CI = -0.15 to -0.02,
and p = 0.01) were taken into account. For finality compared to the use of
a placebo, the findings suggest that LDK does not exhibit significant
differences in terms of pain reduction and functionality. Moreover, no
specific dosages are identified to support the use of LDK in the reduction
in NP.<br/>Copyright &#xa9; 2024 by the authors.

<10>
Accession Number
2031570815
Title
Goal-Directed Fluid Therapy Using Pulse Pressure Variation in Thoracic
Surgery Requiring One-Lung Ventilation: A Randomized Controlled Trial.
Source
Journal of Clinical Medicine. 13(18) (no pagination), 2024. Article
Number: 5589. Date of Publication: September 2024.
Author
Punzo G.; Beccia G.; Cambise C.; Iacobucci T.; Sessa F.; Sgreccia M.;
Sacco T.; Leone A.; Congedo M.T.; Meacci E.; Margaritora S.; Sollazzi L.;
Aceto P.
Institution
(Punzo, Beccia, Cambise, Iacobucci, Sessa, Sgreccia, Sacco, Leone,
Sollazzi, Aceto) Department of Emergency, Anesthesiological and
Reanimation Sciences, Fondazione Policlinico Universitario Agostino
Gemelli IRCCS, Rome 00168, Italy
(Congedo, Meacci, Margaritora) Department of General Thoracic Surgery,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168,
Italy
(Meacci, Margaritora) Department of Translational Medicine and Surgery,
Universita Cattolica del Sacro Cuore, Rome 00168, Italy
(Sollazzi, Aceto) Department of Basic Biotechnological Science, Intensive
Care and Peri-Operative Clinics, Universita Cattolica del Sacro Cuore,
Rome 00168, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Intraoperative fluid management based on pulse pressure
variation has shown potential to reduce postoperative pulmonary
complications (PPCs) and improve clinical outcomes in various surgical
settings. However, its efficacy and safety have not been assessed in
patients undergoing thoracic surgery with one-lung ventilation.
<br/>Method(s): Patients scheduled for pulmonary lobectomy using uniportal
video-assisted thoracic surgery approach were randomly assigned to two
groups. In the PPV group, fluid administration was guided by the pulse
pressure variation parameter, while in the near-zero group, it was guided
by conventional hemodynamic parameters. The primary outcome was the
partial pressure of oxygen (PaO<inf>2</inf>)/ fraction of inspired oxygen
(FiO<inf>2</inf>) ratio 15 min after extubation. The secondary outcomes
included extubation time, the incidence of postoperative pulmonary
complications in the first three postoperative days, and the length of
hospital stay. <br/>Result(s): The PaO<inf>2</inf>/FiO<inf>2</inf> ratio
did not differ between the two groups (364.48 +/- 38.06 vs. 359.21 +/-
36.95; p = 0.51), although patients in the PPV group (n = 44) received a
larger amount of both crystalloids (1145 +/- 470.21 vs. 890 +/- 459.31, p
= 0.01) and colloids (162.5 +/- 278.31 vs 18.18 +/- 94.68, p = 0.002)
compared to the near-zero group (n = 44). No differences were found in
extubation time, type and number of PPCs, and length of hospital stay.
<br/>Conclusion(s): PPV-guided fluid management in thoracic surgery
requiring one-lung ventilation does not improve pulmonary gas exchange as
measured by the PaO<inf>2</inf>/FiO<inf>2</inf> ratio and does not seem to
offer clinical benefits. Additionally, it results in increased fluid
administration compared to fluid management based on conventional
hemodynamic parameters.<br/>Copyright &#xa9; 2024 by the authors.

<11>
Accession Number
2031570766
Title
In-Hospital Graft Occlusion in Post-Coronary Artery Bypass Grafting
Patients in the Early Postoperative Period: A Systematic Review and
Meta-Analysis.
Source
Journal of Clinical Medicine. 13(18) (no pagination), 2024. Article
Number: 5514. Date of Publication: September 2024.
Author
Salikhanov I.; Koechlin L.; Gahl B.; Zellweger M.J.; Haaf P.; Muller C.;
Berdajs D.
Institution
(Salikhanov, Koechlin, Gahl, Berdajs) Department of Cardiac, Surgery,
University Hospital Basel, Basel 4031, Switzerland
(Zellweger, Haaf, Muller) Department of Cardiology, University Hospital
Basel, Basel 4031, Switzerland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Objectives: The objectives of this paper are to evaluate the incidence of
early graft occlusion during hospital stays following coronary bypass
surgery (CABG) and to assess the factors influencing the odds of
in-hospital early graft occlusion. <br/>Method(s): Reports evaluating the
early in-hospital occlusion of coronary bypass grafts were identified
through PubMed, Embase, and Cochrane databases. The primary endpoint was
to determine the incidence of early graft occlusion following CABG before
discharge and to identify and quantify the impact of demographic,
clinical, and procedural risk factors on the occurrence of early graft
occlusion. The meta-analysis was conducted using a random-effects
inverse-variance model with the DerSimonian-Laird estimator, assessing
incidence rates, risk factors, and study heterogeneity, with statistical
analysis performed using Stata. <br/>Result(s): A total of 22 studies with
35,798 patients were included in the analysis. The overall incidence of
in-hospital early graft occlusion was 5% (95% CI: 3% to 7%). In studies
using symptom-driven patency assessment, the incidence of occlusion was
2%, whereas in those employing systematic graft patency assessment, it was
6%. Only the presence of a vein graft OR 2.13 (95% CI: 1.19-3.82) was
significantly associated with in-hospital graft occlusion.
<br/>Conclusion(s): The incidence of in-hospital early graft occlusion
seems substantially underestimated if imaging is restricted only to
symptomatic patients. Moreover, female gender, increased PI, and the
presence of a composite graft could also be potential risk factors for
this complication.<br/>Copyright &#xa9; 2024 by the authors.

<12>
Accession Number
2034806637
Title
Efficacy of intravenous iron supplementation in reducing transfusion risk
following cardiac surgery: an updated meta-analysis of randomised
controlled trials.
Source
British Journal of Anaesthesia. (no pagination), 2024. Date of
Publication: 2024.
Author
Hung K.-C.; Chang L.-C.; Ho C.-N.; Hsu C.-W.; Yu C.-H.; Wu J.-Y.; Lin
C.-M.; Chen I.-W.
Institution
(Hung, Ho, Yu, Lin) Department of Anesthesiology, Chi Mei Medical Center,
Tainan City, Taiwan (Republic of China)
(Hung) Department of Hospital and Health Care Administration, College of
Recreation and Health Management, Chia Nan University of Pharmacy and
Science, Tainan City, Taiwan (Republic of China)
(Chang) Department of Anesthesiology, E-Da Hospital, I-Shou University,
Kaohsiung City, Taiwan (Republic of China)
(Ho) School of Medicine, College of Medicine, National Sun Yat-sen
University, Kaohsiung City, Taiwan (Republic of China)
(Hsu) Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung City, Taiwan
(Republic of China)
(Wu) Department of Nutrition, Chi Mei Medical Center, Tainan City, Taiwan
(Republic of China)
(Chen) Department of Anesthesiology, Chi Mei Medical Center, Liouying,
Tainan City, Taiwan (Republic of China)
Publisher
Elsevier Ltd
Abstract
Background: Previous meta-analyses of intravenous iron supplementation for
reducing red blood cell (RBC) transfusion risk after cardiac surgery were
inconclusive because of limited data. This updated meta-analysis
incorporates recent evidence. <br/>Method(s): Major databases were
searched on May 2, 2024 for randomised controlled trials comparing the
incidence of RBC transfusion between adult patients receiving intravenous
iron supplementation and those receiving controls (i.e. oral iron or
placebo) after cardiac surgery. The secondary outcomes included the number
of RBC units transfused, postoperative haemoglobin levels, iron status,
complications, and length of hospital stay. Trial sequential analysis was
conducted to examine the robustness of evidence. <br/>Result(s): Fourteen
randomised controlled trials including 2043 subjects were identified.
Intravenous iron supplementation was found to reduce the RBC transfusion
risk compared with controls (relative risk 0.77, 95% confidence interval
[CI] 0.65-0.91, P=0.002, n=1955, I²=61%, certainty of evidence:
moderate). The trial sequential analysis supported the robustness of the
evidence. Furthermore, haemoglobin levels were higher in the intravenous
iron supplementation group on postoperative days 4-10 (mean difference
0.17 g dl^-1, 95% CI 0.06-0.29, n=1989) and >21 days (mean
difference 0.66 g/dl^-1, 95% CI 0.36-0.95, n=1008).
Postoperative iron status also improved with Intravenous iron
supplementation, particularly on postoperative days 4-10. There were no
significant differences in other outcomes, including mortality.
<br/>Conclusion(s): Intravenous iron supplementation can reduce RBC
transfusion risk and improve postoperative haemoglobin level and iron
status after cardiac surgery, supporting the implementation of Intravenous
iron supplementation in perioperative blood management strategies.
Systematic review protocol: CRD42024542206 (PROSPERO).<br/>Copyright
&#xa9; 2024 British Journal of Anaesthesia

<13>
Accession Number
2031578196
Title
A Narrative Review of Pain in Pediatric Oncology: The Opioid Option for
Procedural and Surgical Pain.
Source
Pediatric Drugs. (no pagination), 2024. Date of Publication: 2024.
Author
Hall E.A.; Shelton C.M.; Hagemann T.M.; Jasmin H.M.; Grey K.; Anghelescu
D.L.
Institution
(Hall, Shelton, Hagemann) Department of Clinical Pharmacy and
Translational Science, University of Tennessee Health Science Center,
Memphis, TN, United States
(Jasmin) Health Sciences Library, University of Tennessee Health Science
Center, Memphis, TN, United States
(Grey) College of Pharmacy, University of Tennessee Health Science Center,
Memphis, TN, United States
(Anghelescu) Department of Global Pediatric Medicine, St. Jude Children's
Research Hospital, Memphis, TN, United States
Publisher
Adis
Abstract
This narrative review examines the evolving role of opioids in managing
procedural and surgical pain in pediatric oncology patients. The review
evaluates studies on opioid use across various oncological surgeries
including thoracic, abdominal, orthopedic, and neurosurgical procedures,
as well as for common painful procedures such as bone marrow aspirations
and lumbar punctures. While opioids remain important for acute procedural
and postoperative pain management in pediatric oncology patients, there is
an increasing emphasis on multimodal, opioid-sparing approaches. The
evidence presented within this review highlights the growing focus on
judicious postoperative opioid prescribing to mitigate risks of adverse
effects and persistent use or potential misuse. The review synthesizes
findings from studies investigating various analgesic regimens, including
the use of regional anesthesia techniques like epidural analgesia and
peripheral nerve blocks, which have shown promise in reducing opioid
requirements. For procedural pain, the review explores the efficacy of
combining opioids with sedatives like midazolam or propofol, as well as
the potential of ketamine as an opioid-sparing alternative. Key findings
indicate that opioid-sparing techniques can effectively reduce overall
opioid consumption without compromising pain control or patient
satisfaction. Several studies demonstrated that regional anesthesia
techniques and non-opioid adjuncts can significantly lower postoperative
opioid requirements across various surgical procedures. For procedural
pain, ketamine-based regimens often showed comparable or superior pain
control to opioid-based approaches, with some studies reporting better
patient satisfaction. This review also addresses the importance of
tailored postoperative opioid prescribing, with some studies presenting
algorithms to predict outpatient opioid needs more accurately. These
approaches aim to ensure adequate pain control while minimizing excess
opioid dispensing.<br/>Copyright &#xa9; The Author(s) 2024.

<14>
Accession Number
2031621164
Title
Optimizing Anticoagulation in Valvular Heart Disease: Navigating NOACs and
VKAs.
Source
Journal of Personalized Medicine. 14(9) (no pagination), 2024. Article
Number: 1002. Date of Publication: September 2024.
Author
Ouatu A.; Buliga-Finis O.N.; Tanase D.M.; Badescu M.C.; Dima N.; Floria
M.; Popescu D.; Richter P.; Rezus C.
Institution
(Ouatu, Buliga-Finis, Tanase, Badescu, Dima, Floria, Popescu, Richter,
Rezus) Faculty of General Medicine, "Grigore T. Popa" University of
Medicine and Pharmacy, 16 University Street, Iasi 700115, Romania
(Ouatu, Buliga-Finis, Tanase, Badescu, Dima, Floria, Popescu, Rezus)
Department of Internal Medicine, IIIrd Medical Clinic, "Sf. Spiridon"
Emergency Hospital, 1 Independentei Street, Iasi 700111, Romania
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Non-vitamin K antagonist oral anticoagulants
(NOACs) have demonstrated similar effectiveness and safety profiles to
vitamin K antagonists (VKAs) in treating nonvalvular atrial fibrillation
(AF). Given their favorable pharmacological profile, including the rapid
onset and offset of action, fixed dosing, and predictable pharmacokinetics
with a consistent dose-response relationship, reducing the need for
frequent blood tests, researchers have investigated the potential of NOACs
in patients with AF and valvular heart disease (VHD). <br/>Method(s):
Clinical trials, excluding patients with mechanical prosthetic valves or
moderate/severe mitral stenosis, have shown the benefits of NOACs over
VKAs in this population. However, there is a need for further research to
determine if these findings apply to mechanical valve prostheses and
NOACs. <br/>Result(s): Several ongoing randomized controlled trials are
underway to provide more definitive evidence regarding NOAC treatment in
moderate to severe rheumatic mitral stenosis. Importantly, recent trials
that included patients with atrial fibrillation and bioprosthetic valves
(also transcatheter heart valves) have provided evidence supporting the
safety of NOACs in this specific patient population. Ongoing research aims
to clearly define the specific scenarios where NOACs can be safely and
effectively prescribed for various types of VHD, including moderate/severe
mitral stenosis and mechanical valves. <br/>Conclusion(s): The aim of this
review is to accurately identify the specific situations in which NOACs
can be prescribed in patients with VHD, with a focus centered on each type
of valvulopathy.<br/>Copyright &#xa9; 2024 by the authors.

<15>
Accession Number
2034815302
Title
A Three-Day Prehabilitation Program is Cost-Effective for Preventing
Pulmonary Complications after Heart Valve Surgery: A Health Economic
Analysis of a Randomized Trial.
Source
Reviews in Cardiovascular Medicine. 25(9) (no pagination), 2024. Article
Number: 323. Date of Publication: September 2024.
Author
Huang W.; Wang Y.; Luo Z.; Zhang X.; Yang M.; Su J.; Guo Y.; Yu P.
Institution
(Huang, Luo, Zhang, Yang, Su, Yu) Department of Rehabilitation Medicine,
West China Hospital, Sichuan University, Sichuan, Chengdu 610041, China
(Wang, Guo) Department of Cardiac Surgery, West China Hospital, Sichuan
University, Sichuan, Chengdu 610041, China
Publisher
IMR Press Limited
Abstract
Background: While prehabilitation (pre surgical exercise) effectively
prevents postoperative pulmonary complications (PPCs), its
cost-effectiveness in valve heart disease (VHD) remains unexplored. This
study aims to evaluate the cost-effectiveness of a three-day
prehabilitation program for reducing PPCs and improving quality adjusted
life years (QALYs) in Chinese VHD patients. <br/>Method(s): A
cost-effectiveness analysis was conducted alongside a randomized
controlled trial featuring concealed allocation, blinded evaluators, and
an intention-to-treat analysis. In total, 165 patients scheduled for
elective heart valve surgery at West China Hospital were randomized into
intervention and control groups. The intervention group participated in a
three-day prehabilitation exercise program supervised by a physiotherapist
while the control group received only standard preoperative education.
Postoperative hospital costs were audited through the Hospital Information
System, and the EuroQol five-dimensional questionnaire was used to provide
a 12-month estimation of QALY. Cost and effect differences were calculated
through the bootstrapping method, with results presented in
cost-effectiveness planes, alongside the associated cost-effectiveness
acceptability curve (CEAC). All costs were denominated in Chinese Yuan
(CNY) at an average exchange rate of 6.73 CNY per US dollar in 2022.
<br/>Result(s): There were no statistically significant differences in
postoperative hospital costs (8484 versus 9615 CNY, 95% CI -2403 to 140)
or in the estimated QALYs (0.909 versus 0.898, 95% CI -0.013 to 0.034)
between the intervention and control groups. However, costs for
antibiotics (339 versus 667 CNY, 95% CI -605 to -51), nursing (1021 versus
1200 CNY, 95% CI -330 to -28), and electrocardiograph monitoring (685
versus 929 CNY, 95% CI -421 to -67) were significantly lower in the
intervention group than in the control group. The CEAC indicated that the
prehabilitation program has a 92.6% and 93% probability of being
cost-effective in preventing PPCs and improving QALYs without incurring
additional costs. <br/>Conclusion(s): While the three-day prehabilitation
program did not significantly improve health-related quality of life, it
led to a reduction in postoperative hospital resource utilization.
Furthermore, it showed a high probability of being cost-effective in both
preventing PPCs and improving QALYs in Chinese patients undergoing valve
surgery. Clinical Registration Number: This trial is registered in the
Chinese Clinical Trial Registry (URL: https://www.chictr.org.cn/) with the
registration identifier ChiCTR2000039671.<br/>Copyright &#xa9; 2024 The
Author(s). Published by IMR Press.

<16>
Accession Number
2034822903
Title
Response to comment on: "Effect of remimazolam versus propofol on
hypotension after anesthetic induction in patients undergoing coronary
artery bypass grafting: A randomized controlled trial".
Source
Journal of Clinical Anesthesia. 99 (no pagination), 2024. Article Number:
111643. Date of Publication: December 2024.
Author
Nam K.; Ju J.-W.
Institution
(Nam, Ju) Department of Anesthesiology and Pain Medicine, Seoul National
University Hospital, Seoul National University College of Medicine, Seoul,
South Korea
Publisher
Elsevier Inc.

<17>
Accession Number
2034803706
Title
Imaging-guided PCI improves outcomes in patients with multivessel disease
a meta-analysis of randomized and observational trials comparing treatment
of ACS.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2024. Date of
Publication: 2024.
Author
Saganowich J.; Powell J.; Mixon T.A.; Exaire J.E.; Otsuki H.; Fearon W.;
Widmer R.J.
Institution
(Saganowich, Powell, Mixon, Widmer) Texas A&M School of Medicine, Bryan,
TX, United States
(Mixon, Exaire, Widmer) Division of Cardiology, Department of Internal
Medicine Baylor Scott and White, Temple, TX, United States
(Otsuki, Fearon) Division of Cardiovascular Medicine and Stanford
Cardiovascular Institute, Stanford University, CA, United States
(Widmer) Medical Director of the Baylor Scott and White Cath/EP Labs &
Research Institute, Temple, TX, United States
Publisher
Elsevier Inc.
Abstract
Objective: This meta-analysis sought to investigate if IVUS-guided PCI
(IVUS-PCI) can improve outcomes compared to standard PCI and CABG in
patients with multivessel CAD. <br/>Background(s): Coronary artery disease
(CAD) is traditionally revascularized by either percutaneous coronary
intervention (PCI) or coronary artery bypass (CABG) with a historical
benefit of CABG over PCI in multivessel CAD. Intravascular
ultrasound-guided PCI (IVUS-PCI) may improve outcomes compared to
angiography alone. <br/>Method(s): We undertook a systematic search using
PubMed, MEDLINE, EMBASE, Web of Science, and Ovid from 2017 through 2022.
We included randomized controlled trials and observational trials
comparing PCI vs CABG for multivessel CAD evaluated by two independent
reviewers. We extracted baseline data and major adverse cardiovascular
events (MACE; death from any cause, MI, stroke, or repeat
revascularization) at one year. Three trials were selected based on study
arm criteria: FAME 3, BEST, and Syntax II. <br/>Result(s): IVUS-PCI
significantly reduced death from any cause (OR 0.45, CI 0.272-0.733, p =
0.001), repeat revascularization (OR 0.62, CI 0.41-0.95, p = 0.03), and
showed a non-significant reduction in MACE (OR 0.74, CI 0.54-1.01, p =
0.054) when compared to CABG. IVUS-PCI significantly reduced MACE (OR
0.52, CI 0.38-0.72, p < 0.001) and showed a non-significant reduction in
death (OR 0.66, CI 0.36-1.18, p = 0.16) and numerically reduced repeat
revascularization (OR 0.66, CI95 0.431-1.02, p = 0.06) when compared to
PCI without IVUS. <br/>Conclusion(s): IVUS-PCI reduces cardiovascular
outcomes in patients with multivessel disease compared to CABG and
angiographically-guided PCI at one year. These results reinforce the
importance of IVUS-PCI in complex CAD and provide evidence for improved
PCI outcomes compared to CABG for multivessel CAD.<br/>Copyright &#xa9;
2024 Elsevier Inc.

<18>
Accession Number
2034775872
Title
Relative Perioperative Analgesic Efficacy of Superficial Versus Deep
Approach of Serratus Anterior Plane Block for Anterior Chest Wall Surgery:
A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Source
Clinical Journal of Pain. (no pagination), 2024. Article Number:
10.1097/AJP.0000000000001249. Date of Publication: 2024.
Author
Singh N.P.; Makkar J.K.; Dhawan I.; Singh N.; Singh P.M.; Siddiqui N.
Institution
(Singh, Siddiqui) Department of Anesthesia and Pain Medicine, Mount Sinai
Hospital, University of Toronto, Toronto, ON, Canada
(Makkar, Dhawan) Department of Anaesthesia and Intensive Care, Post
Graduate Institute of Medical Education and Research, Chandigarh, India
(Singh) Department of Anaesthesia and Critical Care, All India Institute
of Medical Sciences, Sijua, Patrapada, Odisha, Bhubaneswar, India
(Singh) Department of Anesthesia, Washington University, Saint Louis, MO,
United States
Publisher
Lippincott Williams and Wilkins
Abstract
Objectives: Both superficial (s) and deep (d) serratus anterior plane
(SAP) blocks are effective for anterior chest wall surgeries, but there is
little clarity on which is more effective. Hence, we conducted a
systematic review and meta-analysis of randomized control trials (RCT) to
evaluate the comparative efficacy of the two approaches for SAP block
after anterior chest wall surgery. <br/>Material(s) and Method(s): A
systematic literature search was performed using PubMed, Embase, Scopus,
and Cochrane Central Registers of Controlled Trials for eligible RCTs from
inception until August 2023. The primary outcome was opioid consumption
during the first 24 hours of the postoperative period. The secondary
outcomes included pain scores at various intervals, intraoperative opioid
consumption, time to first analgesic request, block-related complications,
opioid-related side effects, and patient satisfaction scores. Statistical
analysis of the pooled data was performed using Review Manager Version
5.3. <br/>Result(s): We identified seven RCTs published between 2020 and
2022, enrolling 371 patients (186 in the sSAP block and 187 in the dSAP
block). Moderate certainty of evidence suggests that both the approaches
(deep and superficial) of SAP block were comparable for 24-hour oral
morphine equivalent consumption with a mean difference (MD) of 3.78 mg
(95% CI -1.70 to 9.29; P=0.18; I²=87%). The results of other
secondary outcomes were comparable, including resting pain scores with an
MD of 0.08 (95% CI -0.27 to 0.43; P=0.67; I²=87%) for early
pain and MD of 0.63 (95% CI -1.28 to 0.01; P=0.05; I²=95%) for
late pain scores, time to first analgesic request with MD of -0.41 hour
(95% CI -1.40 to 0.59; P=0.42; I²=90%), and incidence of PONV
(OR, 1.45 (95% CI 0.72 to 2.90; P=0.30; I²=0%).
<br/>Discussion(s): Current evidence does not support the preference for
one approach of SAP block over the other for postoperative pain. Based on
the available data, we recommend further future trials to determine any
differences between these interventions.<br/>Copyright &#xa9; 2024 Wolters
Kluwer Health, Inc. All rights reserved.

<19>
Accession Number
2031537230
Title
Novel Retractor-Camera System Facilitates Less Traumatic Minimally
Invasive Procedures and Declutters the Operation Field.
Source
Innovations: Technology and Techniques in Cardiothoracic and Vascular
Surgery. (no pagination), 2024. Date of Publication: 2024.
Author
Sazzad F.; Ng W.H.; Feng G.; Moideen I.S.B.M.; Gohary A.E.; Han Kim K.;
Stevens J.C.; Kofidis T.
Institution
(Sazzad, Moideen, Gohary, Han Kim, Stevens, Kofidis) Department of
Surgery, Yong Loo Lin School of Medicine, National University of
Singapore, Kent Ridge, Singapore
(Ng, Feng, Kofidis) Department of Cardiac, Thoracic and Vascular Surgery,
National University Heart Centre, Kent Ridge, Singapore, Singapore
Publisher
SAGE Publications Ltd
Abstract
Objective: To develop a novel endoscopic system that reduces trauma to the
patient and declutters the surgical field for the surgeon in minimally
invasive heart valve surgery. <br/>Method(s): We designed and developed a
retractor-camera combination for minimally invasive heart surgery; the
cable and camera were connected to the underbelly of the left atrial
retractor blade to provide an illuminated, wide-angle view of the mitral
valve. We conducted ex vivo, in vivo, and, ultimately, a first-in-man
randomized, nonanonymized clinical trial on 20 patients who required
minimally invasive mitral valve surgery. Data from the preoperative period
and the immediate postoperative period were gathered, and patients were
followed for 3 months. <br/>Result(s): Our camera-retractor combo
demonstrated safe and efficient exposure and vision in all detailed
studies. The total operation time for the intervention group (316.5 +/-
65.1 min) was slightly shorter than for the control group (317.5 +/- 50.8
min). There was no significant difference in the ability to provide
exposure of the mitral valve and surrounding left atrial tissue for both
control and test articles. The novel camera-retractor reduced clutter in
the operation field substantially and eliminated chest penetration for the
camera. We also observed that the camera did not fog, did not stain with
blood, and did not require frequent corrections to its position.
<br/>Conclusion(s): We launch a novel atrial retraction-imaging platform
that is less invasive for the patient and eliminates clutter and redundant
movements for the surgeon.<br/>Copyright &#xa9; The Author(s) 2024.

<20>
Accession Number
645396034
Title
Prophylactic non-invasive positive pressure ventilation reduces
complications and length of hospital stay after invasive thoracic
procedures: a systematic review.
Source
Journal of physiotherapy. (no pagination), 2024. Date of Publication: 26
Sep 2024.
Author
da Conceicao Dos Santos E.; Monteiro R.L.; Fonseca Franco de Macedo J.R.;
Poncin W.; Lunardi A.C.
Institution
(da Conceicao Dos Santos) Master and Doctoral Programs in Physical
Therapy, Universidade Cidade de Sao Paulo, Sao Paulo, Brazil; Department
of Biological and Health Sciences. Universidade Federal do Amapa, Macapa,
Brazil
(Monteiro) Department of Biological and Health Sciences. Universidade
Federal do Amapa, Macapa, Brazil
(Fonseca Franco de Macedo) Service de Pneumologie, Cliniques
Universitaires Saint-Luc, Brussels, Belgium
(Poncin) Service de Pneumologie, Cliniques Universitaires Saint-Luc,
Brussels, Belgium; Institut de Recherche Experimentale et Clinique (IREC),
Pole de Pneumologie, ORL et Dermatologie, Universite Catholique de
Louvain, Brussels, Belgium
(Lunardi) Master and Doctoral Programs in Physical Therapy, Universidade
Cidade de Sao Paulo, Sao Paulo, Brazil; Physical Therapy Department,
Universidade de Sao Paulo, Sao Paulo, Brazil
Abstract
QUESTION: In patients undergoing invasive thoracic procedures, what are
the effects of prophylactic non-invasive positive pressure ventilation
(NIV)? DESIGN: Systematic review with meta-analysis of randomised trials.
Methodological quality was assessed using the PEDro scale and the
certainty of evidence with the GRADE approach. PARTICIPANTS: Patients
undergoing invasive thoracic procedures. INTERVENTION: Continuous positive
airway pressure (CPAP) or bi-level positive airway pressure (BiPAP).
OUTCOME MEASURES: Length of hospital stay, postoperative pulmonary
complications, need for tracheal intubation, mortality, hypoxaemia,
pulmonary function and adverse events. Meta-analysis was performed for all
outcomes. Subgroup analyses estimated the effects of CPAP and BIPAP
independently. <br/>RESULT(S): Sixteen trials with 1,814 participants were
included. The average quality of the included studies was fair. Moderate
certainty evidence indicated that NIV reduces postoperative pulmonary
complications (RD -0.09, 95% CI -0.15 to -0.04) without increasing the
rate of adverse events (RD 0.01, 95% CI -0.02 to 0.04). Low certainty
evidence indicated that NIV reduces length of hospital stay (MD -1.4 days,
95% CI -2.2 to -0.5) compared with usual care. The effects on intubation
and mortality rates were very close to no effect, indicating that NIV is
safe. Subgroup analyses showed that the evidence for CPAP had more precise
estimates that that for BiPAP. <br/>CONCLUSION(S): NIV reduces
postoperative pulmonary complications and length of stay after invasive
chest procedures without increasing the risk of adverse events.
REGISTRATION: PROSPERO CRD42015019004.<br/>Copyright &#xa9; 2024
Australian Physiotherapy Association. Published by Elsevier B.V. All
rights reserved.

<21>
Accession Number
645393602
Title
Antithrombotic Strategies After Transcatheter Aortic Valve Replacement in
Patients Without an Indication of Oral Anticoagulants: A Network
Meta-Analysis of Randomized Controlled Trials.
Source
Cardiology in review. (no pagination), 2024. Date of Publication: 26 Sep
2024.
Author
Abuelazm M.; Adhikari G.; Amin A.M.; Elhady M.M.; Awad A.K.; Mahmoud A.;
Gonnah A.R.; Abdelazeem B.
Institution
(Awad) From the Department of Medicine, Faculty of Medicine, Ain-Shams
University, Cairo, Egypt
(Abuelazm, Mahmoud) Department of Medicine, Faculty of Medicine, Tanta
University, Egypt
(Adhikari) Department of Medicine, Banner University Medical Center,
Tucson, AZ, United States
(Amin) Department of Medicine, Faculty of Medicine, Mansoura University,
Mansoura, Egypt
(Elhady) Department of Medicine, Faculty of Medicine, Benha University,
Egypt
(Awad) Department of Medicine, Faculty of Medicine, Galala University,
Suez, Egypt
(Gonnah) Department of Medicine, Imperial College Healthcare NHS Trust,
London, United Kingdom; and
(Abdelazeem) Department of Cardiology, West Virginia University,
Morgantown, WV, United States
Abstract
Single-antiplatelet therapy (SAPT) has been a standard of care
posttranscatheter aortic valve replacement with no clear evidence exist
using direct oral anticoagulants (DOACs), vitamin K antagonists (VKA), or
dual antiplatelet agents (DAPT); thus we aim to compare the safety and
efficacy of the various antithrombotic strategies after transcatheter
aortic valve replacement. We performed a network meta-analysis using a
frequentist framework, pooling dichotomous outcomes using risk ratio (RR),
and continuous data using mean difference, along with the corresponding
95% confidence interval (CI). Nine randomized controlled trials with 4193
patients were included, 567 patients were in the VKA group, 591 patients
in the SAPT group, 1571 patients in the DAPT group, and 1464 patients in
the DOACs group. Only DOAC showed a statistically significant higher risk
of all-cause mortality [RR of 1.88 (95% CI: 1.07-3.28)] with no
statistically significant difference between our arms in terms of
mortality. For minor bleeding, DAPT had a significant higher risk with RR
of 1.53 (95% CI: 1.04-2.25), while for major bleeding, DAPT and DOAC had a
significant higher risk with RR of 2.36 (95% CI: 1.27-4.40) and 4.74 (95%
CI: 2.05-10.92), respectively. There was no significant difference in
terms of stroke and life-threatening bleeding. Moreover, only DOAC showed
a significantly lower risk for valve thrombosis, when compared to other
strategies [RR: 0.24 (95% CI: 0.13-0.46)]. Overall, SAPT had lower major
bleeding events compared to other arms. There were no differences in the
outcomes of stroke, myocardial infarction, or life-threatening bleeding
outcomes. However, DOACs significantly reduced valve thrombosis compared
to VKAs.<br/>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights
reserved.

<22>
Accession Number
645393358
Title
Corrigendum to 'Trunk stabilising exercises promote sternal stability in
patients after median sternotomy for heart valve surgery: a randomised
trial' [J Physiother 2022;68:197-202.
Source
Journal of physiotherapy. (no pagination), 2024. Date of Publication: 25
Sep 2024.
Author
Essam El-Sayed Felaya E.-S.; Abd Al-Salam E.H.; Abd El-Azeim A.S.
Institution
(Essam El-Sayed Felaya) Department of Physical Therapy for Internal
Medicine, Faculty of Physical Therapy, Cairo University, Giza, Egypt
(Abd Al-Salam) Department of Diagnostic Imaging, National Heart Institute,
Giza, Egypt
(Abd El-Azeim) Department of Basic Science, Faculty of Physical Therapy,
Cairo University, Giza, Egypt

<23>
Accession Number
2031590426
Title
Effects of early mobilization in elderly patients undergoing cardiac
surgery.
Source
Irish Journal of Medical Science. (no pagination), 2024. Date of
Publication: 2024.
Author
Ceylan I.; Mhmood A.H.; Al-Janabi R.Q.K.
Institution
(Ceylan) Department of Hand Rehabilitation, School of Physical Therapy and
Rehabilitation, Kirsehir Ahi Evran University, Kirsehir, Turkey
(Mhmood, Al-Janabi) Department of Physiotherapy and Rehabilitation,
Al-Bitar Cardiac Surgery Hospital, Baghdad, Iraq
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Although early mobilization is associated with improved
outcomes in postoperative cardiac patients, implementation of early
mobilization in elderly patients is still a challenge. <br/>Aim(s): In
this study, we aimed to design and assess an early mobilization program
for cardiac rehabilitation. <br/>Method(s): We conducted a clinical trial
in elderly patients aged over 65 years after coronary artery bypass graft
surgery. Patients were randomly assigned to an early mobilization group
(Group A) or a routine therapy group (Group B). Short-Form International
Physical Activity Questionnaire (SF-IPAQ), to assessment balance Time Up
and Go (TUG), to assessment functional capacity the 2-min walking test
(2MWT) and the short physical performance battery (SPPB) were used as a
reference to formulate and monitor the early mobilization regimen.
<br/>Result(s): A total of 100 patients were enrolled (n = 50 per group).
The mean walking distance in Group A was significantly higher at 135.6 +/-
9.29 than the mean walking distance in Group B which was lower at 123.4
+/- 8.48. Also, the patients in Group B had a mean SF-IPAQ of 389.44 with
an SD of 85.7, P < 0.001, whereas the mean SF-IPAQ amount in Group A was
556.16 with an SD of 91.47. In early mobilization group, a strong positive
connection was indicated by the correlation coefficient of r = 0.957
between the amount of SF-IPAQ and 2 MWT and there was a significant
negative association r = - 0.768 between 2MWT and TUG. <br/>Conclusion(s):
Our study's findings suggest that early mobilization and functional
exercises enhanced balance, functionality, and life quality for older
cardiac patients.<br/>Copyright &#xa9; The Author(s), under exclusive
licence to Royal Academy of Medicine in Ireland 2024.

<24>
Accession Number
2031550179
Title
Comprehensive geriatric assessment, and related interventions, to improve
outcomes for older patients undergoing transcatheter aortic valve
implantation (TAVI): a systematic review.
Source
European Geriatric Medicine. (no pagination), 2024. Date of Publication:
2024.
Author
Chin K.; Jones R.; Lester E.; Hegarty A.; Thielemans L.; Schiff R.
Institution
(Chin, Jones, Lester, Hegarty, Thielemans, Schiff) Department of Ageing
and Health, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH,
United Kingdom
(Schiff) King's College London, London WC2R 2LS, United Kingdom
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Aim: To review the evidence for using Comprehensive Geriatric Assessment,
or related interventions, to improve outcomes for older patients
undergoing Transcatheter Aortic Valve Implantation (TAVI).
<br/>Finding(s): There lacks evidence for use of CGA, or related
interventions, in older adults undergoing TAVI due to the low quality of
studies. Message: Further research is required to investigate whether CGA
improves outcomes for older adults undergoing TAVI.<br/>Copyright &#xa9;
The Author(s) 2024.

<25>
Accession Number
2034808187
Title
Letter to the editor regarding "Effect of remimazolam versus propofol on
hypotension after anesthetic induction in patients undergoing coronary
artery bypass grafting: A randomized controlled trial".
Source
Journal of Clinical Anesthesia. 99 (no pagination), 2024. Article Number:
111644. Date of Publication: December 2024.
Author
D'Andria Ursoleo J.; Bottussi A.; Agosta V.T.; Monaco F.
Institution
(D'Andria Ursoleo, Bottussi, Agosta, Monaco) Department of Anesthesia and
Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60,
Milan 20132, Italy
Publisher
Elsevier Inc.

<26>
Accession Number
2034803978
Title
Acetylsalicylic acid alone or in combination with either enoxaparin or
unfractionated heparin for postoperative thromboprophylaxis in coronary
artery bypass surgery patients. A randomised clinical trial assessing
surrogate outcomes.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2024. Date of
Publication: 2024.
Author
Lorenzen U.S.; Arendrup H.; Johansson P.I.; Jakobsen J.C.
Institution
(Lorenzen) Department of Vascular Surgery, Rigshospitalet, Copenhagen,
Denmark
(Arendrup) Department of Thoracic Surgery, Rigshospitalet, Copenhagen,
Denmark
(Johansson) CAG Center for Endotheliomics, Rigshospitalet, Copenhagen,
Denmark
(Jakobsen) Copenhagen Trial Unit, Capitol Region, Copenhagen, Denmark
(Jakobsen) Department of Regional Health Research, The Faculty of Heath
Sciences, University of Southern Denmark, Denmark
(Johansson) Department of Clinical Medicine, University of Copenhagen,
Copenhagen, Denmark
Publisher
Elsevier Inc.
Abstract
Introduction: Coronary artery bypass graft surgery has considerable
effects on patient haemostasis. Heparins as thromboprophylaxis may be
beneficial but may also increase the risk of bleeding complications.
<br/>Objective(s): To assess the effects of heparins on haemostasis in
post-coronary artery bypass graft patients. <br/>Method(s): Across one
year, we randomised 60 participants scheduled for an elective coronary
artery bypass graft-procedure with or without aortic valve replacement.
The trial was a prospective, open-label (though blinded for the
laboratory), randomised, single-centre trial with three intervention
groups (n = 20 in each): group 1 received acetylsalicylic acid, group 2
received subcutaneous low molecular weight heparin and acetylsalicylic
acid, and group 3 received intravenous unfractionated heparin and
acetylsalicylic acid. Primary outcomes were platelet activation
(Multiplate ASPI-test) and time to clot initiation (TEG R-time). We
secondly assessed several additional Multiplate and TEG parameters.
<br/>Result(s): Group 3 (intravenous unfractionated heparin) compared with
group 1 (acetylsalicylic acid alone) showed evidence of 1) increased clot
initiation time (R-time + 0.9 min; 95 % CI: +0.4 to +1.4 min; P = 0.009),
and 2) decreased 30-min lysis (-1.3 %; 95 % CI: -2.1 to -0.5 %; P = 0.02).
The remaining analyses of primary and secondary outcomes showed no
evidence of a difference between the three groups. <br/>Discussion(s):
Intravenous unfractionated heparins may increase the clot initiation time
post-operatively after coronary artery bypass graft surgery and reduce
lysis. Otherwise, there seems to be no effect of low molecular weight or
unfractionated heparin on haemostatic parameters after coronary artery
bypass surgery patients.<br/>Copyright &#xa9; 2024 The Authors

<27>
Accession Number
645392038
Title
Safety implications of mask use: a systematic review and evidence map.
Source
BMJ evidence-based medicine. (no pagination), 2024. Date of Publication:
26 Sep 2024.
Author
Farah W.; Abusalih M.F.; Hasan B.; Lees E.H.; Fleti F.; Elkhatib W.Y.;
Johnson B.D.; Toups G.; Wolf M.; Murad M.H.
Institution
(Farah, Abusalih, Hasan, Fleti, Murad) Evidence-Based Practice Center,
Mayo Clinic, Rochester, MN, United States
(Farah) Division of Pulmonary and Critical Care Medicine, Mayo Clinic,
Rochester, MN, United States
(Abusalih, Hasan, Lees, Fleti, Elkhatib, Toups, Wolf, Murad) Division of
Public Health, Infectious Diseases, Occupational Medicine, Mayo Clinic,
Rochester, MN, United States
(Johnson) Division of Preventive Cardiology, Mayo Clinic, Rochester, MN,
United States
Abstract
BACKGROUND: Widespread use of respiratory protection masks has become a
critical component of public health response. <br/>OBJECTIVE(S): This
systematic review synthesises the evidence on the acute physiological,
cognitive and psychological impacts associated with different types of
masks and provides an evidence map of research gaps. <br/>METHOD(S): A
comprehensive search from 2000 to 2023 was conducted across multiple
databases (MEDLINE, EMBASE, Cochrane databases, Scopus and PubMed). An
umbrella systematic overview was conducted for physiological outcomes
using existing systematic reviews. We conducted de novo systematic reviews
for cognitive and psychological outcomes. Pairs of independent reviewers
determined eligibility, extracted data and assessed risk of bias.
Certainty at an outcome level was appraised using the Grading of
Recommendations Assessment, Development and Evaluation approach.
<br/>RESULT(S): The search resulted in 13370 potential citations, leading
to the inclusion of nine systematic reviews for physiological outcomes (87
primary studies) and 10 primary studies for cognitive and psychological
outcomes (3815 participants), with the majority of participants being
healthy adults. Studies evaluating physiological outcomes demonstrated
that various types of masks have little to no significant difference in
heart rate (surgical mask (mean difference (MD): 0.96 (-1.01 to 2.93)),
N95 mask (MD: 1.63 (-2.79 to 6.05)) and cloth mask (MD: -0.94 (-6.39 to
4.52))) or respiratory rate during rest or exercise (surgical mask (MD:
-1.35 (-3.00 to 0.29)), N95 mask (MD: 0.10 (-3.10 to 3.29)) and cloth mask
(MD: -2.57 (-6.44 to 1.29)) (low certainty for most outcomes)). Mask use
may be associated with very small changes in minute ventilation (surgical
mask (MD: -13.9 (-20.30 to -7.53)) and N95 mask (MD: -16.3 (-28.7 to
-3.9))), tidal volume (surgical mask (MD: -0.14 (-0.23 to -0.05)) and N95
mask (MD: -0.10 (-0.33 to 0.13))), oxygen saturation (surgical mask (MD:
-0.59% (-0.87 to -0.30)), N95 mask (MD: -0.35% (-0.75 to 0.05)) and cloth
mask (MD: -0.50% (-1.23; 0.24))), carbon dioxide partial pressure
(surgical mask (standardised MD (SMD): 1.17 (0.70 to 1.64)) and N95 mask
(SMD: 0.43 (0.08 to 0.79))) and exercise performance (surgical mask (SMD:
-0.12 (-0.39 to 0.15)), N95 mask (SMD: -0.42 (-0.76 to -0.08)) and cloth
mask (SMD: -0.26 (-0.54 to 0.02)) (low certainty for most outcomes)).
Studies evaluating cognitive outcomes showed mixed results. Some studies
reported reduced mental workload, and others showed no significant effect
or decreased performance. The impact on attention, errors and reaction
time was variable. These studies were small and at moderate to high risk
of bias. Evidence was insufficient to estimate the effect of mask use on
psychological outcomes (claustrophobia, depression and anxiety) as these
studies were small, non-longitudinal and at high risk of bias.
<br/>CONCLUSION(S): This evidence map provides a comprehensive insight
into the multifaceted impact of respiratory protection mask use, and
highlights the limited certainty in the available body of evidence. This
evidence map supports the development of future research
agenda.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2024. Re-use
permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ.

<28>
Accession Number
2034752834
Title
Procedural and one-year outcomes of robotic-assisted versus manual
percutaneous coronary intervention.
Source
EuroIntervention. 20(1) (pp 56-65), 2024. Date of Publication: 2024.
Author
Bay B.; Kiwus L.M.; Gossling A.; Koester L.; Blaum C.; Schrage B.;
Clemmensen P.; Blankenberg S.; Waldeyer C.; Seiffert M.; Brunner F.J.
Institution
(Bay, Kiwus, Gosling, Koester, Blaum, Schrage, Clemmensen, Blankenberg,
Waldeyer, Seiffert, Brunner) Department of Cardiology, University Heart &
Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
(Bay, Schrage, Clemmensen, Blankenberg, Waldeyer, Seiffert, Brunner)
German Center for Cardiovascular Research (DZHK), partner site
Hamburg/Kiel/ Lubeck, Hamburg, Germany
(Bay, Gosling, Schrage, Clemmensen, Blankenberg, Seiffert, Brunner) Center
for Population Health Innovation (POINT), University Heart & Vascular
Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg,
Germany
Publisher
Europa Group
Abstract
BACKGROUND: Robotic-assisted percutaneous coronary intervention (rPCI) has
proven to be feasible and safe. Comparative analyses of rPCI versus manual
PCI (mPCI) are scarce. AIMS: We aimed to investigate procedural aspects
and outcomes of rPCI using the second-generation CorPath GRX Vascular
Robotic System compared with mPCI in patients with chronic coronary
syndrome and non-ST-segment elevation myocardial infarction acute coronary
syndrome. <br/>METHOD(S): From January to April 2021, 70 patients
underwent rPCI at the University Heart & Vascular Center Hamburg-Eppendorf
and were recruited into the INTERCATH study. By propensity score matching,
a control cohort of 210 patients who underwent mPCI from 2015-2021 was
identified. Co-primary endpoints were one-year all-cause mortality and
major adverse cardiovascular events (MACE) as a composite of
cardiovascular death, unplanned target lesion revascularisation,
myocardial infarction, and stroke. <br/>RESULT(S): The median age of the
patients (n=280) was 70.7 (25^th percentile-75^th
percentile: 62.0-78.0) years, and 24.6% were female. The Gensini score
(28.5 [16.2-48.1] vs 28.0 [15.5-47.0]; p=0.78) was comparable between rPCI
versus mPCI. During the PCI procedure, total contrast fluid volume did not
differ, whilst longer fluoroscopy times (20.4 min [13.8-27.2] vs 14.4 min
[10.4-24.3]; p=0.001) were documented in the rPCI versus mPCI cohort.
After 12 months of follow-up, neither all-cause mortality (p=0.22) nor
MACE (p=0.25) differed between the groups. <br/>CONCLUSION(S): rPCI was
associated with longer fluoroscopy times compared with mPCI, though
without increased use of contrast medium. One-year follow-up revealed no
differences in all-cause mortality or MACE, supporting the safety of a
robotic-assisted approach.<br/>Copyright &#xa9; Europa Digital &
Publishing 2024. All rights reserved.

<29>
Accession Number
2031555022
Title
Preoperative bioelectrical impedance, measured phase angle, and hand-grip
strength as predictors of postoperative outcomes in patients undergoing
cardiac surgery: a systematic review.
Source
BMC Cardiovascular Disorders. 24(1) (no pagination), 2024. Article Number:
515. Date of Publication: December 2024.
Author
Arero A.G.; Dassie G.A.
Institution
(Arero, Dassie) Department of Public Health, Adama Hospital Medical
College, Baltimore, MD, United States
Publisher
BioMed Central Ltd
Abstract
Background: Postoperative problems are a major danger for patients after
heart surgery. Predicting postoperative outcomes for cardiac surgery is
limited by current preoperative evaluations. Handgrip strength (HGS)
testing and bioelectrical impedance analysis (BIA) may provide extra ways
to identify individuals at risk of surgical problems, enhancing risk
assessment and results. <br/>Objective(s): The purpose of this systematic
review is to assess the utility of measured phase angle (PA), HGS, and
bioelectrical impedance as perioperative risk markers in adult patients
undergoing elective heart surgery. <br/>Method(s): The PRISMA principles
were followed in this review. We searched all available electronic
databases, including the Science Direct search engine and PubMed, MEDLINE,
EMBASE, Cochrane Library, Web of Science, PsycINFO, CINAHL, Google
Scholar, Scopus, and the Science Direct search engine, from their creation
to the present, as well as the medRxiv pre-print site. We considered
studies with adult subjects undergoing elective heart surgery who were
monitored for problems after surgery and had perioperative BIA and HGS
testing. <br/>Result(s): As a result, out of the 1544 pieces of research
that were discovered, eight studies were deemed suitable for inclusion in
the review and supplied data from 2781 people. The findings demonstrated a
substantial correlation between poor preoperative PA and a higher risk of
serious postoperative morbidity, as well as prolonged hospital stays.
Furthermore, poor HGS and low PA were linked to greater death rates.
Additionally, there was a strong correlation found between low PA and HGS
and longer stays in the ICU, as well as an increased chance of dying from
all causes in a year. In conclusion these results imply that preoperative
HGS and PA may be significant indicators of postoperative results and may
assist in identifying patients who are more vulnerable to problems and
death.<br/>Copyright &#xa9; The Author(s) 2024.

<30>
Accession Number
2021351585
Title
Risk factors of post-traumatic stress disorder after hospitalization in a
pediatric intensive care unit: a systematic literature review.
Source
European Child and Adolescent Psychiatry. 33(9) (pp 2991-3001), 2024. Date
of Publication: September 2024.
Author
de Pellegars A.; Cariou C.; Le Floch M.; Duverger P.; Boussicault G.;
Riquin E.
Institution
(de Pellegars, Boussicault) Department of Pediatric Intensive Care,
University Hospital of Angers, Angers, France
(Cariou, Le Floch, Duverger, Riquin) Department of Child and Adolescent
Psychiatry, University Hospital of Angers, Angers, France
(Duverger, Riquin) Reference Center for Learning Disabilities, Nantes
University Hospital, Nantes, France
(Duverger, Riquin) Laboratory of Psychology, LPPL EA4638, University of
Angers, Angers, France
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
The number of studies on post-traumatic stress disorder after
hospitalization in a pediatric intensive care unit raised since 2004. The
objective of this systematic review was to summarize and critically
examine the literature about risk factors for these children to develop
post-traumatic stress disorder following admission to an intensive care
unit. The data sources were PubMed, Cochrane, Web of Science, PsycInfo,
SUDOC, Scopus, and ScienceDirect. Studies were selected if they were in
English or French and published between 01/01/2004 and 31/01/2022. Studies
were excluded if patients were less than 1 month old and if no
post-traumatic stress disorder was found. The internal validity and risk
of bias were assessed using the National Institutes of Health Study
Quality Assessment Tools for observational studies and the Ottawa Scale
was used for the interventional study. The search yielded 523 results and
22 articles met inclusion criteria. Three common risk factors were
identified from the data: parental post-traumatic stress disorder
(especially in mothers), severity of illness and delusional memories.
Internalizing behavior in children, acute parent and child stress,
emergency admission and sepsis are also potential risk factors that
require further investigation. The prevalence of this pathology is
substantial (between 14 and 36%) and increasing awareness among
pediatricians and psychologists seems necessary. Prevention programs are
being studied to reduce the incidence of post-traumatic stress disorder in
this population. Child and adolescent psychiatry liaison should
collaborate with pediatric teams to support this objective.<br/>Copyright
&#xa9; The Author(s), under exclusive licence to Springer-Verlag GmbH
Germany 2023.

<31>
Accession Number
2034723846
Title
Effectiveness and safety of emergency transcatheter aortic valve
replacement in patients with severe aortic stenosis complicated by
cardiogenic shock: A systematic review and meta-analysis.
Source
Heart and Lung. 69 (pp 62-70), 2025. Date of Publication: 01 Jan 2025.
Author
Deng Y.; Wei S.; Zhu L.; Tao L.
Institution
(Deng, Tao) Northern Jiangsu People's Hospital Affiliated to Yangzhou
University, Yangzhou 225001, China
(Deng, Zhu) Medical College of Yangzhou University, Yang zhou 225001,
China
(Deng, Tao) Northern Jiangsu People's Hospital, Yang zhou 225001, China
(Wei, Zhu) Taizhou People's Hospital affiliated towith Nanjing Medical
University, Taizhou 225300, China
Publisher
Elsevier Inc.
Abstract
Background: The application of transcatheter aortic valve replacement
(TAVR) has been developed on different populations in many clinical
studies. However, research dedicated to the application of emergency TAVR
in patients with aortic stenosis (AS) experiencing cardiogenic shock is
limited. <br/>Objective(s): To investigate the safety and effectiveness of
emergency TAVR in AS patients with circulatory collapse. <br/>Method(s):
Studies on the application of emergency TAVR in AS patients with
cardiogenic shock were screened from PubMed, Web of Science, and Embase
databases. Two researchers independently screened the literature-extracted
data and conducted a meta-analysis was conducted using STATA 16.0
software. <br/>Result(s): 17 studies comprising 36,886 patients undergoing
emergency TAVR and 8,530 patients undergoing emergency SAVR or BAV.
Emergency TAVR showed no difference in valve implantation success rate
compared to elective TAVR. At 30-day endpoints comparison, emergency TAVR
exhibited significantly higher all-cause mortality and readmission rates
than elective TAVR (RR=2.73 95 %CI 2.04-3.65, P < 0.01; RR=1.2 95 %CI
0.9-1.6, P < 0.01), but reduced mortality risk compared to emergency
SAVR/BAV (RD=-0.15 95 %CI -0.25 to -0.04, P = 0.005). At one year
post-operation, people with emergency TAVR continued to have higher
all-cause mortality than elective TAVR (RR=1.55 95 %CI 1.37-1.74, P <
0.01) but similar with emergency SAVR/BAV (RD=-0.04 95 %CI -0.33 to 0.25,
P = 0.796). Rates of severe bleeding and new-onset renal dialysis were
higher after emergency TAVR, compared to elective TAVR, while the
incidences of permanent pacemaker implantation, severe paravalvular
leakage and stroke were similar. <br/>Conclusion(s): Despite emergency
TAVR having higher readmission and mortality rates compared to elective
TAVR, it is a relatively safe and effective treatment in cases of
cardiogenic shock compared to emergency BAV/SAVR.<br/>Copyright &#xa9;
2024 Elsevier Inc.

<32>
Accession Number
2034549428
Title
Incidence of High-Grade AV Block Requiring Permanent Pacemaker
Implantation After TTVR: A Meta-Analysis.
Source
JACC: Cardiovascular Interventions. 17(18) (pp 2195-2196), 2024. Date of
Publication: 23 Sep 2024.
Author
Gupta K.; Jain V.; Kakar T.S.; Nguyen F.; Rangavajla G.; Merchant F.M.;
Lahiri M.
Publisher
Elsevier Inc.

<33>
Accession Number
2032576099
Title
Central versus peripheral cannulation for acute type A aortic dissection:
A meta-analysis of over 14,000 patients.
Source
American Journal of Surgery. 237 (no pagination), 2024. Article Number:
115780. Date of Publication: November 2024.
Author
Samadzadeh Tabrizi N.; Sa M.P.; Jacquemyn X.; Yousef S.; Brown J.A.;
Serna-Gallegos D.; Sultan I.
Institution
(Samadzadeh Tabrizi) Albany Medical College, Albany, NY, United States
(Sa, Yousef, Brown, Serna-Gallegos, Sultan) Department of Cardiothoracic
Surgery, University of Pittsburgh, PA, United States
(Sa, Yousef, Brown, Serna-Gallegos, Sultan) UPMC Heart and Vascular
Institute, University of Pittsburgh Medical Center, United States
(Jacquemyn) Department of Cardiovascular Sciences, KU Leuven, Leuven,
Belgium
Publisher
Elsevier Inc.
Abstract
Objective: The optimal cannulation strategy for patients with acute type A
aortic dissections (ATAAD) is unclear. <br/>Method(s): A systematic search
was performed to identify all studies comparing aortic and non-aortic
cannulation in patients undergoing ATAAD repair. The primary endpoint was
overall survival. The secondary endpoints were operative mortality,
postoperative stroke, renal failure, renal replacement therapy,
paraplegia, and mesenteric ischemia. Pooled meta-analyses with aggregated
and reconstructed time-to-event data were performed. <br/>Result(s):
Twenty-three studies were included (aortic: 3904; non-aortic: 10,719).
Ten-year overall survival was 61.1 % and 58.4 % for aortic and non-aortic
cannulation, respectively (HR 1.07; 95 % CI 0.92-1.25; p = 0.38). No
statistically significant difference was observed for operative mortality
(p = 0.10), stroke (p = 0.89), renal failure (p = 0.83), or renal
replacement therapy (p = 0.77). <br/>Conclusion(s): Patients undergoing
surgery for ATAAD can undergo aortic cannulation with similar outcomes to
those who undergo non-aortic cannulation.<br/>Copyright &#xa9; 2024

<34>
Accession Number
2032384438
Title
Comprehensive analysis of donor-site chest deformities after autologous
costal cartilage microtia reconstruction: A systematic review.
Source
Journal of Plastic, Reconstructive and Aesthetic Surgery. 94 (pp 128-140),
2024. Date of Publication: July 2024.
Author
Kim J.; Park C.; Oh K.S.; Lim S.Y.
Institution
(Kim, Park, Lim) Department of Plastic Surgery, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, South Korea
(Oh) Department of Plastic surgery, Kangbuk Samsung Hospital, Sungkyunkwan
University School of Medicine, Seoul, South Korea
Publisher
Churchill Livingstone
Abstract
Background: Autologous costal cartilage has gained widespread acceptance
as an important material for ear reconstruction in patients with microtia.
Despite its recognition as being "worth the trade-off," attention should
be directed toward donor-site deformities. This systematic review focused
on existing English literature related to microtia reconstruction and
aimed to reveal the incidence of chest wall deformities and assess the
effectiveness of the various proposed surgical techniques aimed at
reducing donor-site morbidities. <br/>Method(s): A comprehensive search
was conducted on Pubmed and OVID using the keywords "microtia," and "chest
deformity" or "rib harvest." Articles were screened based on predefined
inclusion and exclusion criteria. Data acquisition encompassed patient
demographics, employed surgical techniques, methods for evaluating chest
deformity, and incidence of associated complications. <br/>Result(s):
Among the 362 identified articles, 21 met the inclusion criteria. A total
of 2600 cases involving 2433 patients with microtia were analyzed in this
review. Perichondrium preservation during cartilage harvesting led to a
significant reduction in chest deformities. However, the wide incidence
range (0% to 50%) and the lack of specific assessment methods suggested
potential underestimation. Computed tomography revealed reduced chest wall
growth in the transverse and sagittal directions, resulting in decreased
thoracic area. Innovative surgical techniques have shown promising results
in reducing chest deformities. <br/>Conclusion(s): Although a quantitative
analysis was not feasible, objective evidence of deformities was
established through computed tomography scans. This analysis highlighted
the need for dedicated studies with larger sample sizes to further advance
our understanding of chest wall deformities in microtia
reconstruction.<br/>Copyright &#xa9; 2024

<35>
Accession Number
2023746802
Title
Clinical outcomes of different revascularization approaches for patients
with multi-vessel coronary artery disease: A network meta-analysis.
Source
Perfusion (United Kingdom). 39(6) (pp 1041-1056), 2024. Date of
Publication: September 2024.
Author
Hasan S.U.; Pervez A.; Naseeb M.W.; Rajput B.S.; Faheem A.; Hameed I.; Sa
M.P.; Zubair M.M.
Institution
(Hasan, Pervez) Aga Khan University Hospital, Karachi, Pakistan
(Naseeb, Rajput, Faheem) Dow University of Health Sciences, Karachi,
Pakistan
(Hameed) Department of Cardiothoracic Surgery, Yale School of Medicine,
New Haven, CT, United States
(Sa) Department of Cardiac Surgery, Lankenau Heart Institute, Wynnewood,
PA, United States
(Zubair) Department of Cardiac Surgery, Smidt Heart Institute,
Cedars-Sinai Medical Center, Los Angeles, CA, United States
Publisher
SAGE Publications Ltd
Abstract
Background: As surgical techniques continue to evolve, the optimal
approach for revascularizing multi-vessel coronary artery disease (CAD)
remains a matter of ongoing debate. Accordingly, our objective was to
compare and contrast various surgical techniques utilized in the
management of multi-vessel CAD. <br/>Method(s): A systematic literature
review was performed using PubMed, Embase, and Cochrane central register
of controlled trials from inception to May 2022. Random-effects network
meta-analysis was performed for the primary outcome; target vessel
revascularization (TVR), and secondary outcomes; mortality, major adverse
cardiac and cerebrovascular events, postoperative myocardial infarction,
new-onset atrial fibrillation, stroke, new-onset dialysis, in patients
undergoing percutaneous coronary intervention (PCI) with a stent, off-pump
coronary bypass graft, on-pump coronary artery bypass graft (ONCABG),
hybrid coronary revascularization, minimally-invasive coronary artery
bypass, or robot-assisted coronary artery bypass (RCAB) surgeries.
<br/>Result(s): A total of 8841 patients were included from 23 studies.
The analysis showed that ONCABG had the highest freedom from TVR, with a
mean (SD) absolute risk of 0.027 (0.029); although ONCABG was found to be
superior to all other methods, it was only significantly better than
first-generation stent PCI. While RCAB did not demonstrate significant
superiority over other treatments, it showed a greater probability of
preventing postoperative complications. Notably, no significant
heterogeneity was calculated for any of the reported outcomes.
<br/>Conclusion(s): ONCABG shows a better rank probability compared to all
other techniques for preventing TVR, while RCAB offers greater freedom
from most postoperative complications. However, given the absence of
randomized controlled trials, these results should be interpreted with
caution.<br/>Copyright &#xa9; The Author(s) 2023.

<36>
Accession Number
2023382125
Title
Percutaneous versus surgical approach to aortic valve replacement with
coronary revascularization: A systematic review andmeta-analysis.
Source
Perfusion (United Kingdom). 39(6) (pp 1152-1160), 2024. Date of
Publication: September 2024.
Author
Guo Y.; Zhang W.; Wu H.
Institution
(Guo) Department of Graduate School, Changzhi Medical College, Shanxi,
Changzhi, China
(Zhang, Wu) Department of Cardiothoracic Surgery, Changzhi People's
Hospital, Shanxi, Changzhi, China
Publisher
SAGE Publications Ltd
Abstract
Objective: The optimal treatment of patients with severe aortic stenosis
(AS) and complex coronary artery disease (CAD) remains controversial. We
conducted a meta-analysis to investigate outcomes of transcatheter aortic
valve replacement (TAVR) with percutaneous coronary intervention (PCI)
versus surgical aortic valve replacement (SAVR) with coronary artery
bypass grafting (CABG). <br/>Method(s): We searched PubMed, Embase, and
Cochrane databases from its inception up to 17 December 2022 for studies
that assessed TAVR + PCI versus SAVR + CABG in patients with AS and CAD.
The primary outcome was perioperative mortality. <br/>Result(s): Six
observational studies including 135,003 patients assessing TAVI + PCI (n =
6988) versus SAVR + CABG (n = 128,015) were included. Compared to SAVR +
CABG, TAVR + PCI was not significantly associated with perioperative
mortality (RR, 0.76; 95% CI, 0.48-1.21; p = 0.25), vascular complications
(RR, 1.85; 95% CI, 0.72-4.71; p = 0.20), acute kidney injury (RR, 0.99;
95% CI, 0.73-1.33; p = 0.95), myocardial infraction (RR, 0.73; 95% CI,
0.30-1.77; p = 0.49), or stroke (RR, 0.87; 95% CI, 0.74-1.02; p = 0.09).
TAVR + PCI significantly reduced the incidence of major bleeding (RR,
0.29; 95% CI, 0.24-0.36; p < 0.01) and length of hospital stay (MD, -1.60;
95% CI, -2.45 to -0.76; p < 0.01), but increased the incidence of
pacemaker implantation (RR, 2.03; 95% CI, 1.88-2.19; p < 0.01). At
follow-up, TAVR + PCI was significantly associated with coronary
reintervention (RR, 3.17; 95% CI, 1.03-9.71; p = 0.04) and a reduced rate
of long-term survival (RR, 0.86; 95% CI, 0.79-0.94; p < 0.01)
<br/>Conclusion(s): In patients with AS and CAD, TAVR + PCI did not
increase perioperative mortality, but increased the rates of coronary
reintervention and long-term mortality.<br/>Copyright &#xa9; The Author(s)
2023.

<37>
Accession Number
2034708107
Title
Effects of psychological interventions on clinical outcomes in patients
with cardiovascular diseases: A systematic review and meta-analysis.
Source
Journal of Psychosomatic Research. 187 (no pagination), 2024. Article
Number: 111938. Date of Publication: December 2024.
Author
Nie Y.; Wang N.; Chi M.; Li A.; Ji S.; Zhu Z.; Li S.; Hou Y.
Institution
(Nie, Wang, Hou) The First Affiliated Hospital of Soochow University,
Suzhou, China
(Nie, Wang, Chi, Li, Ji, Zhu, Li, Hou) School of Nursing, Suzhou Medical
College of Soochow University, Suzhou, China
Publisher
Elsevier Inc.
Abstract
Objective: To perform a systematic review and meta-analysis to evaluate
the effects of psychological interventions on the clinical outcomes of
patients with cardiovascular diseases (CVDs). <br/>Method(s): We searched
PubMed, Web of Science, Embase, the Cochrane Library, and CINAHL from the
establishment of each database to August 1, 2023. Randomized controlled
trials (RCTs) on psychological interventions in patients with CVDs were
included. Statistical analyses were performed using Review Manager 5.3 and
Stata 17.0, and pooled measures were presented as the relative risk (RR)
and 95 % confidence interval (CI). <br/>Result(s): A total of 32 studies
were included, involving 15,814 patients. Our results showed that
psychological interventions could reduce cardiac mortality (RR = 0.81, 95
% CI = 0.68 to 0.96) and the occurrence of myocardial infarction (MI) (RR
= 0.79, 95 % CI = 0.69 to 0.89), arrhythmia (RR = 0.61, 95 % CI = 0.42 to
0.89) and angina (RR = 0.92, 95 % CI = 0.87 to 0.97). However, no
statistically significant differences were detected in the risk of
all-cause mortality, all-cause rehospitalization rates, cardiac
rehospitalization rates, revascularization, heart failure (HF), or stroke
between the psychological intervention and control groups.
<br/>Conclusion(s): Psychological interventions can reduce cardiac
mortality and the occurrence of MI, arrhythmia, and angina in patients
with CVDs. It is crucial to incorporate psychological interventions into
the existing treatment and management of patients with CVDs. High-quality
RCTs should be conducted to explore the optimal psychological intervention
methods and the maximum beneficiaries.<br/>Copyright &#xa9; 2024 Elsevier
Inc.

<38>
Accession Number
2034741354
Title
Proportion and risk factors for hospital-acquired venous thromboembolism
in children: a systematic review and meta-analysis of data from 20 million
individuals in 22 countries.
Source
Research and Practice in Thrombosis and Haemostasis. 8(6) (no pagination),
2024. Article Number: 102541. Date of Publication: August 2024.
Author
Zhou J.; Zhu Y.; Liu Y.; Zhan H.; Niu P.; Chen H.; Zhang J.
Institution
(Zhou, Zhu, Liu, Zhan, Niu, Chen, Zhang) Department of Pharmacy, Fujian
Maternity and Child Health Hospital College of Clinical Medicine for
Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou,
China
Publisher
Elsevier B.V.
Abstract
Background: Hospital-acquired venous thromboembolism (HA-VTE) in children
has been widely regarded. <br/>Objective(s): We aimed to analyze the
proportion and risk factors for HA-VTE in hospitalized children.
<br/>Method(s): We conducted a comprehensive systematic search across 4
databases from 1990 to 2023. Cochran Q test was used to evaluate the
heterogeneity of the effect sizes of study, and I² statistic
was used to quantify the heterogeneity. Pooled estimates were calculated
by the inverse-variance weighted method in a fixed-effect model or a
random-effect model when heterogeneity was low (I² < 25%) or
high (I² > 25%), respectively. <br/>Result(s): In total, 105
original papers and 20,718,294 patients were included in the study, and
the proportion of HA-VTE in children was 4.1% (95% CI, 2.9%-5.2%).
Although the proportion of venous thromboembolism increased over the
various research periods, the differences were not statistically
significant. In the subgroup analysis based on country, the proportion of
pediatric HA-VTE was lowest in the United Kingdom and highest in Spain,
whereas when based on region, the proportion was lowest in Asia and
highest in North America. Multiple HA-VTE risk factors were identified,
including central venous catheter use, age of >10 years, surgery, injury,
infection, obesity, mechanical ventilation, blood transfusion, malignancy,
coagulation and hemorrhagic disorders, and length of hospital stay.
<br/>Conclusion(s): In this study, we systematically analyzed the
proportion and risk factors of HA-VTE in hospitalized children. Our
findings provide valuable insights for the prevention and treatment of
HA-VTE in pediatric patients.<br/>Copyright &#xa9; 2024 The Author(s)

<39>
Accession Number
2034725729
Title
Colchicine in Patients With Coronary Disease Who Underwent Coronary Artery
Bypass Surgery: A Meta-Analysis of Randomized Controlled Trials.
Source
American Journal of Cardiology. 231 (pp 48-54), 2024. Date of Publication:
15 Nov 2024.
Author
Kirov H.; Caldonazo T.; Runkel A.; Medin D.; Fischer J.; Dallan L.R.;
Mukharyamov M.; Mejia O.A.; Jatene F.B.; Doenst T.
Institution
(Kirov, Caldonazo, Runkel, Medin, Fischer, Mukharyamov, Doenst) Department
of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena,
Germany
(Dallan, Mejia, Jatene) Department of Cardiovascular Surgery, Heart
Institute - University of Sao Paulo Medical School, Sao Paulo, Brazil
Publisher
Elsevier Inc.
Abstract
Recent randomized evidence has shown that low-dose colchicine lowers the
risk of cardiovascular events in patients with chronic coronary artery
disease. Colchicine has also been used in coronary artery bypass grafting
(CABG), with individual studies suggesting protective effects for
postoperative atrial fibrillation (POAF). We performed a meta-analysis of
studies assessing the effect of colchicine on outcomes in CABG surgery. We
systematically searched 3 libraries (MEDLINE, Web of Science, and the
Cochrane Library), selecting all randomized control trials including
patients who underwent CABG and were randomized for perioperative
administration of colchicine versus standard of care. The primary outcome
was incidence of POAF. The inverse variance method (DerSimonian&Laird) and
random-effects model were performed. The leave-one-out analysis was
carried out as a sensitivity analysis to address possible outliers. From
205 screened studies, 5 met the inclusion criteria and were selected. The
data from 839 patients were included in the final analysis. The included
studies were published between 2014 and 2022. The perioperative
administration of colchicine was associated with the reduction of POAF
rates after CABG compared with standard of care (relative risk 0.54, 95%
confidence interval 0.40 to 0.73, p <0.01). The leave-one-out analysis
confirmed the robustness of the analysis, with minimal variations of the
confidence interval. This meta-analysis of randomized studies suggests
that the perioperative administration of colchicine is associated with
significant reduction of POAF after CABG.<br/>Copyright &#xa9; 2024 The
Author(s)

<40>
Accession Number
2034725138
Title
Low-dose colchicine for the prevention of cardiovascular events after
percutaneous coronary intervention: Rationale and design of the COL BE PCI
trial.
Source
American Heart Journal. 278 (pp 61-71), 2024. Date of Publication:
December 2024.
Author
De Cock E.; Kautbally S.; Timmermans F.; Bogaerts K.; Hanet C.; Desmet W.;
Gurne O.; Vranckx P.; Hiltrop N.; Dujardin K.; Vanduynhoven P.; Vermeersch
P.; Pirlet C.; Hermans K.; Van Reet B.; Ferdinande B.; Aminian A.; Dewilde
W.; Guedes A.; Simon F.; De Roeck F.; De Vroey F.; Jukema J.W.; Sinnaeve
P.; Buysschaert I.
Institution
(De Cock, Buysschaert) Department of Cardiology, AZ Sint-Jan Brugge AV,
Bruges, Belgium
(De Cock, Timmermans) Department of Cardiology, Ghent University Hospital,
Ghent, Belgium
(Kautbally, Gurne) Department of Cardiology, Cliniques Universitaires
St-Luc, Universite Catholique de Louvain, Brussels, Belgium
(Bogaerts) Department of Public Health and Primary Care, KU Leuven,
I-BioStat, Leuven, Belgium and UHasselt, I-BioStat, Diepenbeek, Belgium
(Hanet, Guedes) Department of Cardiology, Universite Catholique de
Louvain, Mont Godinne, Yvoir, Belgium
(Desmet, Sinnaeve) Department of Cardiovascular Sciences, University of
Leuven, Leuven, Belgium
(Desmet, Sinnaeve) Belgium & Department of Cardiovascular Medicine,
University Hospitals Leuven, Leuven, Belgium
(Vranckx) Department of Cardiology and Intensive Care Medicine, Jessa
Ziekenhuis, Hasselt, Belgium
(Hiltrop) Department of Cardiology, AZ Groeninge, Kortrijk, Belgium
(Dujardin) Department of Cardiology, AZ Delta, Roeselare, Belgium
(Vanduynhoven) Department of Cardiology, Arrhythmia Clinic, ASZ Aalst,
Aalst, Belgium
(Vermeersch) Department of Cardiology, ZNA (Ziekenhuis Netwerk Antwerpen)
Middelheim, Antwerp, Belgium
(Pirlet) Department of Cardiology, Citadelle Liege, Liege, Belgium
(Hermans) Department of Cardiology, AZ Sint-Lucas Ghent, Ghent, Belgium
(Van Reet) Department of Cardiology, AZ Turnhout, Turnhout, Belgium
(Ferdinande) Department of Cardiology, Hospital Oost-Limburg, Genk,
Belgium
(Aminian) Department of Cardiology, Centre Hospitalier Universitaire de
Charleroi, Charleroi, Belgium
(Dewilde) Department of Cardiology, Imelda Hospital Bonheiden, Bonheiden,
Belgium
(Simon) Department of Cardiology, Clinique Saint-Luc Bouge, Namur, Belgium
(De Roeck) Department of Cardiology, University Hospital Antwerp, Edegem,
Belgium
(De Vroey) Department of Cardiology, Grand Hopital de Charleroi,
Charleroi, Belgium
(Jukema) Department of Cardiology, Leiden University Medical Center,
Leiden, Netherlands
(Jukema) Netherlands Heart Institute, Utrecht, Netherlands
Publisher
Elsevier Inc.
Abstract
Introduction: Patients with coronary artery disease (CAD) remain
vulnerable to future major atherosclerotic events after revascularization,
despite effective secondary prevention strategies. Inflammation plays a
central role in the pathogenesis of CAD and recurrent events. To date,
there is no specific anti-inflammatory medicine available with proven
effective, cost-efficient, and favorable benefit-risk profile, except for
colchicine. Initial studies with colchicine have sparked major interest in
targeting atherosclerotic events with anti-inflammatory agents, but
further studies are warranted to enforce the role of colchicine role as a
major treatment pillar in CAD. Given colchicine's low cost and established
acceptable long-term safety profile, confirming its efficacy through a
pragmatic trial holds the potential to significantly impact the global
burden of cardiovascular disease. <br/>Method(s): The COL BE PCI trial is
an investigator-initiated, multicenter, double-blind, event-driven trial.
It will enroll 2,770 patients with chronic or acute CAD treated with
percutaneous coronary intervention (PCI) at 19 sites in Belgium, applying
lenient in- and exclusion criteria and including at least 30% female
participants. Patients will be randomized between 2 hours and 5 days
post-PCI to receive either colchicine 0.5 mg daily or placebo on top of
contemporary optimal medical therapy and without run-in period. All
patients will have baseline hsCRP measurements and a Second Manifestations
of Arterial Disease (SMART) risk score calculation. The primary endpoint
is the time from randomization to the first occurrence of a composite
endpoint consisting of all-cause death, spontaneous non-fatal myocardial
infarction, non-fatal stroke, or coronary revascularization. The trial is
event-driven and will continue until 566 events have been reached,
providing 80% power to detect a 21 % reduction in the primary endpoint
taking a premature discontinuation of 15% into account. We expect a trial
duration of approximately 44 months. <br/>Conclusion(s): The COL BE PCI
Trial aims to assess the effectiveness and safety of administering
low-dose colchicine for the secondary prevention in patients with both
chronic and acute coronary artery disease undergoing PCI. Trial
registration: ClinicalTrials.gov: NCT06095765.<br/>Copyright &#xa9; 2024
Elsevier Inc.

<41>
[Use Link to view the full text]
Accession Number
2034645637
Title
CCTA-Guided Invasive Coronary Angiography in Patients With CABG: A
Multicenter, Randomized Study.
Source
Circulation: Cardiovascular Interventions. 17(9) (pp e014045), 2024. Date
of Publication: 01 Sep 2024.
Author
Tsigkas G.; Toulgaridis F.; Apostolos A.; Kalogeropoulos A.; Karamasis
G.V.; Vasilagkos G.; Pappas L.; Toutouzas K.; Tsioufis K.; Korkonikitas
P.; Tsiafoutis I.; Hamilos M.; Ziakas A.; Kanakakis I.; Moulias A.;
Zampakis P.; Davlouros P.; Papanikolaou A.; Spyropoulou P.; Chlorogiannis
D.D.; Chamakioti M.; Spanou E.; Kartas N.; Vithoulkas N.; Sideris A.;
Zacharoulis A.; Lampropoulos K.; Georgopoulos S.; Synetos A.; Latsios G.;
Alexopoulos D.; Argentos S.; Xenogiannis I.; Triantafyllou K.;
Patsilinakos S.; Fagkrezos D.; Mantis C.; Pappa A.; Koutouzis M.;
Sakellaropoulou A.; Kochiadakis G.; Kladou E.; Sianos G.; Kouparanis A.;
Karagiannidis E.; Daios S.; Papoutsis D.; Sertedaki E.
Institution
(Tsigkas, Vasilagkos, Moulias, Davlouros) Department of Cardiology,
University Hospital of Patras, Greece
(Zampakis) Department of Radiology, University Hospital of Patras, Greece
(Toulgaridis) Second Department of Cardiology, 'Evangelismos' General
Hospital of Athens, Greece
(Pappas) First Department of Cardiology, 'Evangelismos' General Hospital
of Athens, Greece
(Apostolos, Toutouzas, Tsioufis) First Department of Cardiology,
'Hippocration' University Hospital of Athens, Greece
(Kalogeropoulos) Division of Cardiology, Department of Medicine, Stony
Brook University, New York, United States
(Karamasis) Second Department of Cardiology, 'Attikon' University Hospital
of Athens, Greece
(Korkonikitas) Department of Cardiology, 'Agia Olga' General Hospital of
Nea Ionia, Athens, Greece
(Tsiafoutis) First Department of Cardiology, 'Red Cross' General Hospital
of Athens, Greece
(Hamilos) Department of Cardiology, 'PAGNI' University Hospital of
Heraklion Creta, Greece
(Ziakas) First Department of Cardiology, 'AHEPA' University Hospital of
Thessaloniki, Greece
(Kanakakis) Department of Cardiology, 'Alexandra' General Hospital of
Athens, Greece
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Coronary computed tomography angiography (CCTA) in patients
with post-coronary artery bypass graft (CABG) has a high diagnostic
accuracy for visualization of grafts. Invasive coronary angiography (ICA)
in patients with CABG is associated with increased procedural time,
contrast agent administration, radiation exposure, and complications,
compared with non-CABG patients. The aim of this multicenter, randomized
controlled trial was to compare the strategy of CCTA-guided ICA versus
classic ICA in patients with prior CABG. <br/>METHOD(S): Patients with
prior CABG were randomly assigned (1:1 ratio) to have a CCTA before ICA
(CCTA-ICA, group A) or not (ICA-only, group B). The primary end point of
the study was the total volume (milliliters) of the contrast agent
administered. <br/>RESULT(S): A total of 251 patients were randomized, and
225 were included in analysis; 110 in group A and 115 in group B. The
total contrast volume was higher in group A (184.5 [143-255] versus 154
[102-240] mL; P = 0.001). The contrast volume administered during the
invasive procedure was lower in group A (101.5 [60-151] versus 154
[102-240]; P<0.001). Total fluoroscopy time was decreased in group A (480
[259-873] versus 594 [360-1080] seconds; P = 0.027), but total effective
dose was increased (24.1 [17.7-32] versus 10.8 [5.6-18] mSv; P<0.001). The
rate of contrast-induced nephropathy, periprocedural complications, and
major adverse cardiac events during 3 to 5 and 30 days did not differ
significantly between the 2 groups. <br/>CONCLUSION(S): A CCTA-directed
ICA strategy for patients with CABG is associated with expedition of the
invasive procedure, and less fluoroscopy time, at the cost of higher total
contrast volume and effective radiation dose, compared with the classic
ICA approach.<br/>Copyright &#xa9; 2024 American Heart Association, Inc.

<42>
Accession Number
2034641860
Title
Exploring the landscape of oesophageal discontinuity procedures and
creation of cervical oesophagostomy in the modern era: A scoping review
protocol.
Source
BMJ Open. 14(6) (no pagination), 2024. Article Number: e081153. Date of
Publication: 11 Jun 2024.
Author
Bondzi-Simpson A.; Benipal H.; Momoh H.; Matei A.C.; Wakeam E.
Institution
(Bondzi-Simpson, Matei, Wakeam) Department of Surgery, University of
Toronto, Toronto, ON, Canada
(Bondzi-Simpson) Institute of Health Policy Management and Evaluation,
University of Toronto Dalla Lana School of Public Health, Toronto, ON,
Canada
(Benipal) University of Toronto, Toronto, ON, Canada
(Momoh) Medical University of the Americas, Charlestown, Saint Kitts and
Nevis
(Wakeam) Surgery, Division of Thoracic Surgery, University Health Network,
Toronto, ON, Canada
Publisher
BMJ Publishing Group
Abstract
Introduction Oesophageal discontinuity remains a challenge for thoracic
and foregut surgeons globally. Whether arising emergently after
catastrophic oesophageal or gastric disruption or arising in the elective
setting in the case of staged reconstruction for esophagectomy or long gap
atresia in the paediatric population, comprehensive review of this patient
population remains unexplored within the surgical literature. The goal of
this scoping review is to map the landscape of literature exploring the
creation and takedown of cervical oesophagostomy with the intent to answer
four questions (1) What are the primary indications for oesophageal
discontinuity procedures? (2) What are the disease-specific and healthcare
utilisation outcomes for oesophageal discontinuity procedures? (3) What is
the primary indication for reversal procedures? (4) What are the
disease-specific and healthcare utilisation outcomes for reversal
procedures? Methods This review will follow the Arksey and O'Malley (2005)
framework for scoping reviews. Paediatric (<18 years old) and adult (>18
years old) patients, who have received a cervical oesophagostomy in the
context of a gastrointestinal discontinuity procedure or those who have
had reversal of a cervical oesophagostomy, will be included for analysis.
We will search MEDLINE, EMBASE and Cochrane Central Register of Controlled
Trials (CENTRAL) databases for papers from 1990 until 2023. Interventional
trials, prospective and retrospective observational studies, reviews, case
series and qualitative study designs will be included. Two authors will
independently review all titles, abstracts and full texts to determine
which studies meet the inclusion criteria. Ethics and dissemination No
ethics approval is required for this review. Results will be disseminated
through scientific presentations and relevant conferences targeted for
researchers examining upper gastrointestinal/foregut surgery. Registration
details This protocol is registered with Open Science Framework
(osf.io/s3b4g).<br/>Copyright &#xa9; Author(s) (or their employer(s))
2024.

<43>
Accession Number
2034254933
Title
Cardiac rehabilitation recommendations of the Group Exercise
Rehabilitation Sports - Prevention (GERS-P) of the French Society of
Cardiology: 2023 update.
Source
Archives of Cardiovascular Diseases. 117(8-9) (pp 521-541), 2024. Date of
Publication: 01 Aug 2024.
Author
Bigot M.; Guy J.M.; Monpere C.; Cohen-Solal A.; Pavy B.; Iliou M.C.;
Bosser G.; Corone S.; Douard H.; Farrokhi T.; Guerder A.; Guillo P.;
Houppe J.-P.; Pezel T.; Pierre B.; Roueff S.; Thomas D.; Verges B.;
Blanchard J.C.; Ghannem M.; Marcadet D.
Institution
(Bigot) Centre de readaptation cardiaque, Cardiocean, Puilboreau 17138,
France
(Guy) Le Clos Champirol reeducation, Saint-Priest-en-Jarez 42270, France
(Monpere) SMR Dieulefit Sante, Dieulefit 26220, France
(Cohen-Solal) Service de cardiologie, centre de readaptation cardiaque,
hopital Lariboisiere, Assistance publique-Hopitaux de Paris, Inserm
UMRS-942, universite Paris Cite, Paris 75010, France
(Pavy) Service de readaptation cardiovasculaire, CH Loire Vendee Ocean,
Machecoul 44270, France
(Iliou) Centre de readaptation cardiaque, groupe hospitalier Paris
Saint-Joseph, Paris 75014, France
(Bosser) Service de cardiologie pediatrique et congenitale, CHU Nancy,
Vandoeuvre-Les-Nancy 54600, France
(Corone, Farrokhi) Service readaptation cardiaque, centre hospitalier de
Bligny, Briis-sous-Forges 91640, France
(Douard) CHU Bordeaux, Pessac, France
(Guerder) Service de pneumologie, hopital Pitie-Salpetriere, Assistance
publique-Hopitaux de Paris, Paris 75013, France
(Guillo) Centre de readaptation Saint-Yves, Rennes 35000, France
(Houppe) Cardiologue, Saint-Michel L'Observatoire 04870, France
(Pezel) Service de cardiologie, hopital Lariboisiere, AP-HP, universite
Paris Est Creteil, Paris 75010, France
(Pierre) Faculte de medecine, Lyon Sud, Lyon 69310, France
(Roueff) Service de nephrologie, hopital europeen Georges-Pompidou,
Assistance publique-Hopitaux de Paris, Paris 75015, France
(Thomas) Institut de cardiologie Pitie-Salpetriere, AP-HP, Paris 75013,
France
(Verges) Dijon 21000, France
(Blanchard) Montbeliard 25200, France
(Ghannem) Service de cardiologie, hopital de Gonesse, faculte de medecine,
Sousse, Tunisia
(Ghannem) Universite Picardie Jules-Verne, Amiens 80000, France
(Marcadet) Paris 75008, France
Publisher
Elsevier Masson s.r.l.

<44>
Accession Number
2030104186
Title
Ultrasound-guided erector spinae plane block versus thoracic epidural
block for postoperative analgesia in pediatric Nuss surgery: a randomized
noninferiority trial.
Source
Journal of Anesthesia. 38(5) (pp 600-608), 2024. Date of Publication:
October 2024.
Author
Ren Y.; Nie X.; Zhang F.; Ma Y.; Hua L.; Zheng T.; Xu Z.; Gao J.; Zhang J.
Institution
(Ren, Zhang, Ma, Hua, Zheng, Xu, Gao, Zhang) Department of Anesthesiology,
Beijing Children's Hospital, National Center for Children's Health,
Capital Medical University, No. 56, South Lishi Road, Beijing 100045,
China
(Nie) Center for Clinical Epidemiology and Evidence-Based Medicine,
Beijing Children's Hospital, National Center for Children's Health,
Capital Medical University, Beijing 100045, China
Publisher
Springer
Abstract
Purpose: Thoracic epidural anesthesia (TEA) is often used for analgesia
after thoracic surgery. Erector spinae plane block (ESPB) has been
proposed to provide adequate analgesia. We hypothesized that ESPB would be
noninferior to TEA as a part of multimodal analgesia in pediatric patients
undergoing the Nuss procedure. <br/>Method(s): Patients aged 7-18 years
and scheduled for the Nuss procedure were randomly allocated to receive
bilateral single-shot ESPB or TEA and a multimodal analgesic regimen
including parent-controlled intravenous analgesia (PCIA). At 6 h, 12 h, 18
h, and 24 h postoperatively, pain was evaluated using the numeric rating
scale (NRS) and opioid consumption was assessed by counting the number of
PCIA boluses. The joint primary outcomes were the average pain score and
opioid consumption at 24 h after surgery. The secondary outcomes were the
NRS scores and the number of opioid boluses administered at different
postoperative time points, adverse events, and recovery quality.
<br/>Result(s): Three hundred patients underwent randomization, and 286
received ESPB (147 patients) or TEA (139 patients). At 24 h
postoperatively, ESPB was noninferior to TEA in terms of the average NRS
score (mean difference, - 0.1, 95% confidence interval [CI], - 0.3-0.1,
margin = 1, P for noninferiority < 0.001) and the number of opioid boluses
administered (mean difference, - 1.1, 95% CI, - 2.8-0.6, margin = 7, P for
noninferiority < 0.001). Adverse events and patient recovery were
comparable between groups. <br/>Conclusion(s): The results demonstrate
that combined with a multimodal analgesia, ESPB provides noninferior
analgesia compared to TEA with respect to pain score and opioid
consumption among pediatric patients undergoing the Nuss
procedure.<br/>Copyright &#xa9; The Author(s) under exclusive licence to
Japanese Society of Anesthesiologists 2024.

<45>
Accession Number
2034763580
Title
Safety and efficacy of protamine after transcatheter aortic valve
replacement.
Source
Indian Heart Journal. (no pagination), 2024. Date of Publication: 2024.
Author
Kumaraguruparan L.D.; Anandaram A.; Sambandam K.G.; Chidambaram Y.;
Kidambi B.R.; Karthikeyan G.G.; Kasi M.; Abdulkader R.S.; Ramesh S.;
Ramalingam V.; Rajendran R.; Senguttuvan N.B.
Institution
(Kumaraguruparan, Ramesh, Senguttuvan) Department of Cardiology, Sri
Ramachandra Institute of Higher Education and Research (SRIHER), No.1,
Ramachandra Nagar, Porur, Chennai, Tamil Nadu 600116, India
(Anandaram) Department of Internal Medicine, Lehigh Valley Health Network,
Allentown, PA 18101, United States
(Sambandam) Department of Cardiac Anaesthesia, Sri Ramachandra Institute
of Higher Education and Research (SRIHER), No.1, Ramachandra Nagar, Porur,
Chennai, Tamil Nadu 600116, India
(Chidambaram, Kasi) Department of Clinical Research, Sri Ramachandra
Institute of Higher Education and Research (SRIHER), No.1, Ramachandra
Nagar, Porur, Chennai, Tamil Nadu 600116, India
(Kidambi) Department of Cardiology, AI Dhannah Hospital, Ruwais, Abu
Dhabi, United Arab Emirates
(Karthikeyan) Department of Cardiology, PSRI Hospital, New Delhi, India
(Abdulkader) National Institute of Epidemiology, ICMR, Chennai &
Department of Statistics, Manonmaniam Sundaranar University,
Abishekapatti, Tirunelveli, Tamil Nadu, India
(Ramalingam) Department of Cardiology, Velammal Medical College and
Hospital, Madurai, India
(Rajendran) Department of Cardiology, Apollo Hospitals, Trichy, India
Publisher
Elsevier B.V.
Abstract
Transfemoral Trans-catheter Aortic Valve Replacement (TF-TAVR) is a safe
alternative to surgical aortic valve replacement (SAVR). Protamine is used
to reverse heparin and reduce post-TAVR bleeding, but concerns about risks
like valve thrombosis and stroke remain. This systematic review and
meta-analysis, following PRISMA guidelines, found no statistically
significant difference in major bleeding complications between the
protamine and control groups [(3.0 % vs. 14.4 %); RR: 0.56; P = 0.16]. No
differences were noted in life-threatening bleeding, blood transfusions,
30-day mortality, or stroke. Protamine appears safe post-TAVR without
increasing stroke risk, but its effectiveness in reducing bleeding needs
further investigation through a multicentric randomized
study.<br/>Copyright &#xa9; 2024

<46>
Accession Number
2031521284
Title
RETRACTION: Effect of topical application of autologous platelet gel on
sternal wound infection after cardiac surgery: A meta-analysis,
(International Wound Journal, (2023), 21, 3, (e14761), 10.1111/iwj.14761).
Source
International Wound Journal. 21(9) (no pagination), 2024. Article Number:
e70080. Date of Publication: September 2024.
Author
Li Y.; Wu Z.
Publisher
John Wiley and Sons Inc
Abstract
The above article, published online on 29 February 2024, in Wiley Online
Library (http://onlinelibrary.wiley.com/), has been retracted by agreement
between the journal Editor in Chief, Professor Keith Harding; and John
Wiley & Sons, Ltd. It came to the publisher's attention from a third party
that a number of articles shared concerning similarities in format and
structure. Following an investigation by the publisher, the retraction has
been agreed on as the peer review and publishing process for this article
were found to be manipulated.<br/>Copyright &#xa9; 2024 The Author(s).
International Wound Journal published by Medicalhelplines.com Inc and John
Wiley & Sons Ltd.

<47>
Accession Number
2030785190
Title
State-of-the-art percutaneous coronary intervention for left main coronary
artery disease in Japan.
Source
Cardiovascular Intervention and Therapeutics. 39(4) (pp 386-402), 2024.
Date of Publication: October 2024.
Author
Warisawa T.; Sonoda S.; Yamaji K.; Amano T.; Kohsaka S.; Natsuaki M.;
Tsujita K.; Hibi K.; Kobayashi Y.; Kozuma K.
Institution
(Warisawa) Department of Cardiology, NTT Medical Center Tokyo, Tokyo,
Japan
(Sonoda, Natsuaki) Department of Cardiovascular Medicine, Saga University,
5-1-1, Nabeshima, Saga 849-8501, Japan
(Yamaji) Department of Cardiovascular Medicine, Kyoto University Graduate
School of Medicine, Kyoto, Japan
(Amano) Department of Cardiology, Aichi Medical University, Aichi, Japan
(Kohsaka) Department of Cardiology, Keio University School of Medicine,
Tokyo, Japan
(Tsujita) Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, Kumamoto, Japan
(Hibi) Department of Cardiology, Yokohama City University Graduate School
of Medicine, Yokohama, Japan
(Kobayashi) Department of Cardiovascular Medicine, Chiba University
Graduate School of Medicine, Chiba, Japan
(Kozuma) Department of Cardiology, Teikyo University Hospital, Tokyo,
Japan
Publisher
Springer
Abstract
Percutaneous coronary intervention for left main coronary artery disease
(LM-PCI) represents a high-risk yet life-saving procedure that has evolved
significantly over the years. This review outlines the current
state-of-the-art practices for LM-PCI in Japan in detail, emphasizing the
integration of coronary physiology and intracoronary imaging alongside
with evidence-based standardized technique using latest drug-eluting
stents. These advancements enable precise lesion assessment, stent sizing,
and optimal deployment, thereby enhancing procedural safety and efficacy.
Despite discrepancies between current guidelines favoring coronary artery
bypass grafting and real-world practice trends towards increased LM-PCI
adoption, particularly in elderly populations with multiple comorbidities,
careful patient selection and procedural planning are critical. Future
perspectives include further refining LM-PCI through conducting randomized
controlled trials integrating advanced techniques and addressing the issue
of ostial left circumflex lesions and nationwide standardization of
medical care for LM disease. Graphical abstract: (Figure
presented.)<br/>Copyright &#xa9; The Author(s) under exclusive licence to
Japanese Association of Cardiovascular Intervention and Therapeutics 2024.

<48>
Accession Number
2034778211
Title
Machine learning for prediction of transcatheter mitral valve repair
outcomes: A systematic review.
Source
Informatics in Medicine Unlocked. 50 (no pagination), 2024. Article
Number: 101586. Date of Publication: January 2024.
Author
Sacoransky E.; Ke D.Y.J.; Abuzeid W.
Institution
(Sacoransky, Ke, Abuzeid) School of Medicine, Queen's University,
Kingston, ON, Canada
(Abuzeid) Division of Cardiology, Kingston Health Sciences Centre,
Kingston, ON, Canada
Publisher
Elsevier Ltd
Abstract
Background: Transcatheter mitral valve repair (TMVR) has evolved as a
minimally invasive alternative to traditional mitral valve surgery.
Meanwhile, machine learning (ML) offers a promising tool for TMVR risk
stratification due to the lack of established risk scores specifically
tailored for TMVR patients. To address the absence of consensus on its
efficacy, we conducted a systematic review of primary studies that have
utilized ML to predict the success of TMVR. <br/>Method(s): Embase,
MEDLINE, Scopus, Web of Science, PubMed, Google Scholar, and the Cochrane
Library were systematically searched from inception through April 2024. We
included primary studies that used TMVR as the sole interventional
technique for adult MR patients. These studies also had to employ at least
one ML model to predict the success of TMVR. <br/>Result(s): 244
publications were screened, with seven eventually included in this review.
Two studies employed clustering techniques, two utilized extreme gradient
boosting, and three used multiple ML algorithms to predict TMVR outcomes.
Of the four studies that compared the accuracy of ML with traditional
regression models, all four demonstrated higher accuracy with ML, and this
difference was statistically significant in three of the four studies.
<br/>Conclusion(s): To our knowledge, we conducted the first systematic
review of ML methods for prediction of TMVR success in MR treatment. ML
outperformed established risk scores, demonstrating promising potential in
interventional cardiology. Future ML models, trained on larger patient
datasets, may further improve predictive accuracy, and enhance risk
stratification in this population.<br/>Copyright &#xa9; 2024 The Authors

<49>
Accession Number
645374066
Title
Review of Association Between Urinary Tract Infections and
Immunosuppressive Drugs after Heart Transplantation.
Source
Reviews on recent clinical trials. (no pagination), 2024. Date of
Publication: 25 Sep 2024.
Author
Tolou-Ghamari Z.
Institution
(Tolou-Ghamari) Nutrition and Food Security Research Center, Deputy of
Research and Technology, Isfahan University of Medical Sciences, Isfahan,
Iran, Islamic Republic of
Abstract
Management of infections in heart transplant recipients is complex and
crucial. In this population, there is a need for a better understanding of
immunosuppressive trough levels (C0), infectious complications, and
urinary tract infections (UTIs). The purpose of this review was to
understand the association between immunosuppressive trough levels and
UTIs after heart transplantation. A review of scientific literature (n=
100) was conducted based on the topic of interest by searching PUBMED.Gov
(https://pubmed.ncbi.nlm.nih.gov/), Web of Science, and Scopus. The
analysis of bacterial pulmonary infection required the occurrence of new
or deteriorating pulmonary infiltrates and the development of organisms in
cultures of sputum specimens. The diagnosis of UTIs was based on the
result of related signs, pyuria, and a positive urine culture. The
incidence of UTIs was reported as 0.07 episodes/1000 regarding heart
transplantation days. An eightfold increase in the rate of rejection was
noted in heart transplant recipients with higher variability in tacrolimus
C0. There are associations between C0 of immunosuppressive drugs and
clinical presentation of infection complications. Recipients with a low
metabolism of immunosuppressive drugs are more susceptible to infectious
complications. Attention to the biology of herpes viruses, Escherichia
coli, Enterococcus spp., Pseudomonas aeruginosa, and Staphylococcus
saprophyticus after heart transplantation are important, in which some of
them are the most common pathogens responsible for UTIs. Pneumocystis and
cytomegalovirus affect all transplant recipients. Pneumonia due to
bacterial, viral, protozoa, and fungal infections, in addition to UTIs,
are more specific reported types of infections in heart transplant
recipients. Bacterial infections produced by extensively drug-resistant
Enterobacteriaceae, vancomycin-resistant enterococci, and non-fermenting
gramnegative bacteria were reported to increase after
transplantation.<br/>Copyright&#xa9; Bentham Science Publishers; For any
queries, please email at epub@benthamscience.net.

<50>
Accession Number
645373424
Title
Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury
and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical
Trial.
Source
Circulation. (no pagination), 2024. Date of Publication: 25 Sep 2024.
Author
Jia P.; Ji Q.; Zou Z.; Zeng Q.; Ren T.; Chen W.; Yan Z.; Shen D.; Li Y.;
Peng F.; Su Y.; Xu J.; Shen B.; Luo Z.; Wang C.; Ding X.
Institution
(Jia, Zou, Zeng, Ren, Chen, Yan, Shen, Li, Peng, Xu, Shen, Ding)
Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai
Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood
Purification, China (P.J., T.R., W.C., D.S., F.P., B.S., China
(Ji, Wang) Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan
University
(Su, Luo) Cardiac Intensive Care Center, Zhongshan Hospital, Fudan
University
Abstract
BACKGROUND: Remote ischemic preconditioning (RIPC) has 2 time windows for
organ protection: acute and delayed. Previous studies have mainly focused
on the organoprotective effects of acute RIPC. We aimed to determine
whether delayed RIPC can reduce the occurrence of acute kidney injury
(AKI) and postoperative complications in patients undergoing cardiac
surgery. <br/>METHOD(S): This prospective, single-center, double-blind,
randomized controlled trial involved 509 patients at high risk for AKI who
were scheduled for elective cardiac surgery requiring cardiopulmonary
bypass. Patients were randomized to receive RIPC (4 cycles of 5-minute
inflation and 5-minute deflation on 1 upper arm with a blood pressure
cuff) 24 hours before surgery or a sham condition (control group) that was
induced by 4 cycles of 5-minute inflation to a pressure of 20 mmHg
followed by 5-minute cuff deflation. The primary end point was the
incidence of AKI within the prior 7 days after cardiac surgery. The
secondary end points included renal replacement therapy during
hospitalization, change in urinary biomarkers of AKI and markers of
myocardial injury, duration of intensive care unit stay and mechanical
ventilation, and occurrence of nonfatal myocardial infarction, stroke, and
all-cause mortality by day 90. <br/>RESULT(S): A total of 509 patients
(mean age, 65.2+/-8.2 years; 348 men [68.4%]) were randomly assigned to
the RIPC group (n=254) or control group (n=255). AKI was significantly
reduced in the RIPC group compared with the control group (69/254 [27.2%]
versus 90/255 [35.3%]; odds ratio, 0.68 [95% CI, 0.47-1.00]; P=0.048).
There were no significant between-group differences in the secondary end
points of perioperative myocardial injury (assessed by the concentrations
of cardiac troponin T, creatine kinase myocardial isoenzyme, and NT-proBNP
[N-terminal pro-brain natriuretic peptide]), duration of stay in the
intensive care unit and hospital, and occurrence of nonfatal myocardial
infarction, stroke, and all-cause mortality by day 90. <br/>CONCLUSION(S):
Among high-risk patients undergoing cardiac surgery, delayed RIPC
significantly reduced the occurrence of AKI. REGISTRATION: URL:
https://www.chictr.org.cn; Unique identifier: ChiCTR2000035568.

<51>
Accession Number
645372156
Title
Natural biomaterials in the management of the aortic valve pathology.
Biomedical and clinical aspects: A review.
Source
Biomolecules & biomedicine. (no pagination), 2024. Date of Publication:
24 Sep 2024.
Author
Mokryk I.; Nechai I.; Schmitz C.; Stetsyuk I.; Talalaiev O.; Todurov B.
Institution
(Mokryk, Nechai, Stetsyuk, Todurov) Department of Adult Cardiac Surgery,
Heart Institute, Kyiv 02660, Ukraine
(Schmitz, Talalaiev) Auto Tissue Berlin GmbH, Berlin, Germany
Abstract
Heart valve diseases are a prevalent cardiovascular pathology worldwide,
affecting nearly 2.5% of the population. Degenerative aortic stenosis is
the most common form of heart valve disease. The treatment options include
surgical or transcatheter procedures. There are two main categories of
valve prostheses available: mechanical heart valves constructed from
synthetic materials and bioprosthetic heart valves made from natural
biomaterials. The choice of valve type depends on various factors,
including the underlying medical condition, suitability for
anticoagulation, valve durability, and the patient's age and preferences.
Mechanical heart valves have the advantage of long-term durability.
However, patients receiving mechanical implants are subjected to lifelong
anticoagulation therapy with an increased risk of thromboembolism and
bleeding. Natural biomaterials do not require long-term anticoagulation.
However, they experience degenerative changes leading to structural valve
deterioration that may require reoperation. The purpose of this article is
to review the role of natural biological materials used for aortic valve
replacement or repair, assess their biomedical and clinical advantages and
limitations, and analyze the direction and perspectives of future
development.

<52>
Accession Number
645345579
Title
Late Follow-up for a Randomized Trial of Surgical Treatment of Tricuspid
Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device
Implantation.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2024. Date of Publication: 21 Sep 2024.
Author
Pla M.M.; Russell S.D.; Milano C.A.; Chiang Y.; Kang L.; Poehlein E.;
Green C.L.; Benedetti F.; Billard H.; Bryner B.S.; Schroder J.N.;
Daneshmand M.A.; Nicoara A.; DeVore A.D.; Patel C.B.; Bishawi M.
Institution
(Pla, Milano, Kang, Benedetti, Billard, Schroder) Division of
Cardiothoracic Surgery, Duke University Medical Center, Durham, NC, United
States
(Russell, DeVore, Patel) Division of Cardiology, Duke University Medical
Center, Durham, NC, United States
(Chiang) Division of Cardiovascular and Thoracic Surgery, Aurora St.
Luke's Medical Center, Milwaukee, WI, United States
(Poehlein, Green) Department of Biostatistics and Bioinformatics, Duke
University School of Medicine, Durham, NC, United States
(Bryner) Division of Cardiothoracic Surgery, Northwestern University
Feinberg School of Medicine, Chicago, IL, United States
(Daneshmand, Bishawi) Division of Cardiothoracic Surgery, Emory
University, Atlanta, GA, United States
(Nicoara) Department of Anesthesiology, Duke University Medical Center,
Durham, NC, United States
Abstract
OBJECTIVES: We previously reported that concurrent tricuspid valve surgery
(TVS) was not associated with a lower incidence of early RHF among
patients undergoing durable LVAD implantation. This is a follow-up
analysis to further define the clinical impact of concurrent TVS within
12-months of follow-up. <br/>METHOD(S): Patients with moderate or severe
TR on pre-operative echocardiography (n=71) were randomized to either LVAD
implantation alone (No TVS, n=34) or with concurrent TVS (TVS, n=37).
Randomization was stratified by pre-operative right ventricular
dysfunction. Patients were followed for at least 12-months after surgery.
The incidence of RHF was determined using INTERMACS criteria by an
adjudication committee. Functional studies and repeat echocardiography
were performed at 12-months. <br/>RESULT(S): Demographics were similar
between the two arms. At 12-months, the rate of moderate or severe RHF was
50.0% (No TVS) versus 51.4% (TVS). No patients developed RHF between 6-
and 12-months following the procedure. Death from RHF was 5.4% (TVS)
versus 8.8% (No TVS). At 12-months, there was no significant difference in
TR severity between the two arms due to improvement in TR severity in the
No TVS arm. On cardiopulmonary exercise testing at 12+ months, there was
no significant difference in peak oxygen consumption. <br/>CONCLUSION(S):
In patients with significant pre-implant TR, the severity of TR improved
over time in the LVAD implantation alone arm. By 12-months, there is no
significant difference in TR severity between the two arms. This may
account for the lack of difference in late clinical or functional
parameters.<br/>Copyright &#xa9; 2024. Published by Elsevier Inc.

<53>
Accession Number
645342445
Title
Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF
Trial.
Source
Circulation. (no pagination), 2024. Date of Publication: 23 Sep 2024.
Author
Stone G.W.; Lindenfeld J.; Rodes-Cabau J.; Anker S.D.; Zile M.R.; Kar S.;
Holcomb R.; Pfeiffer M.P.; Bayes-Genis A.; Bax J.J.; Bank A.J.; Costanzo
M.R.; Verheye S.; Roguin A.; Filippatos G.; Nunez J.; Lee E.C.;
Laufer-Perl M.; Moravsky G.; Litwin S.E.; Prihadi E.; Gada H.; Chung E.S.;
Price M.J.; Thohan V.; Schewel D.; Kumar S.; Kische S.; Shah K.S.; Donovan
D.J.; Zhang Y.; Eigler N.L.; Abraham W.T.
Institution
(Stone) Zena and Michael A. Wiener Cardiovascular Institute, Icahn School
of Medicine at Mount Sinai, NY, United States
(Lindenfeld) Advanced Heart Failure, Vanderbilt Heart and Vascular
Institute, Nashville, United States
(Rodes-Cabau) Quebec Heart & Lung Institute, Laval University, Quebec City
(Rodes-Cabau) Clinic Barcelona, Spain (J.R.-C.)
(Anker) Department of Cardiology (CVK) of German Heart Center Charite,
Institute of Health Center for Regenerative Therapies (BCRT), German
Centre for Cardiovascular Research (DZHK) partner site Berlin, Charite
University, Germany (S.D.A.), Germany
(Zile) Division of Cardiology, Medical University of South Carolina, Ralph
H. Johnson Department of Veterans Affairs Medical Center
(Kar) Los Robles Regional Medical Center, Thousand Oaks
(Holcomb) MinneapolisUnited States
(Pfeiffer) Penn State Heart and Vascular Institute, PA (M.P.H.), Hershey,
United States
(Bayes-Genis) University Hospital Germans Trias and Pujol de Badalona,
Spain
(Bax) Leiden University Medical Center, Netherlands
(Bank) Allina Health Minneapolis Heart Institute-St-Paul (A.J.B.)
(Costanzo) Midwest Cardiovascular Institute, Naperville, United States
(Verheye) Antwerp Cardiovascular Center, ZNA Middelheim, Belgium
(Roguin) Hillel Yaffe Medical Center, Hadera, Israel
(Filippatos) National and Kapodistrian University of Athens, Attikon
University Hospital, Greece
(Nunez) Hospital Clinico Universitario, INCLIVA, University of Valencia,
Spain
(Lee) Rochester Regional Health
(Laufer-Perl) Tel Aviv Sourasky Medical Center, affiliated with the Tel
Aviv School of Medicine, Tel Aviv University, Israel
(Moravsky) Assaf HaRofeh Medical Center, Beer Yaakov
(Litwin) Medical University of South Carolina
(Prihadi) Antwerp Cardiovascular Center, ZNA Middelheim Hospital, Belgium
(Gada) UPMC Pinnacle, PA (H.G.), Harrisburg, United States
(Chung) Christ Hospital Health Network, Cincinnati, United States
(Price) Scripps Clinic, La Jolla
(Thohan) Mission Health, Ashville, United States
(Schewel) Germany (D.S.), Marienkrankenhaus, Hamburg, Germany
(Kumar) University of Texas Medical Center-Houston (S. Kumar)
(Kische) Vivantes Hospital Friedrichshain, Germany (S. Kische), Berlin,
Germany
(Shah) University of Utah Health
(Donovan) Methodist Cardiology Clinic of San Antonio
(Zhang) Cardiovascular Research Foundation, NY, United States
(Eigler) V-Wave Ltd, Caesarea, Israel
(Eigler) Cedars-Sinai Medical Center, Los Angeles, Mexico
(Abraham) Division of Cardiovascular Medicine, Davis Heart and Lung
Research Institute, Ohio State University Wexner Medical Center
Abstract
BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism
to decrease left atrial pressure and improve heart failure (HF) symptoms
and prognosis. <br/>METHOD(S): Patients with symptomatic HF with any left
ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter
shunt implantation versus a placebo procedure, stratified by reduced
(<=40%) versus preserved (>40%) LVEF. The primary safety outcome was a
composite of device-related or procedure-related major adverse
cardiovascular or neurological events at 30 days compared with a
prespecified performance goal of 11%. The primary effectiveness outcome
was the hierarchical composite ranking of all-cause death, cardiac
transplantation or left ventricular assist device implantation, HF
hospitalization, outpatient worsening HF events, and change in quality of
life from baseline measured by the Kansas City Cardiomyopathy
Questionnaire overall summary score through maximum 2-year follow-up,
assessed when the last enrolled patient reached 1-year follow-up,
expressed as the win ratio. Prespecified hypothesis-generating analyses
were performed on patients with reduced and preserved LVEF.
<br/>RESULT(S): Between October 24, 2018, and October 19, 2022, 508
patients were randomized at 94 sites in 11 countries to interatrial shunt
treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th
percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%)
were women. Median LVEF was reduced (<=40%) in 206 patients (40.6%) and
preserved (>40%) in 302 patients (59.4%). No primary safety events
occurred after shunt implantation (upper 97.5% confidence limit, 1.5%;
P<0.0001). There was no difference in the 2-year primary effectiveness
outcome between the shunt and placebo procedure groups (win ratio, 0.86
[95% CI, 0.61-1.22]; P=0.20). However, patients with reduced LVEF had
fewer adverse cardiovascular events with shunt treatment versus placebo
(annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI,
0.42-0.73]; P<0.0001), whereas patients with preserved LVEF had more
cardiovascular events with shunt treatment (annualized rate 60.2% versus
35.9%; relative risk, 1.68 [95% CI, 1.29-2.19]; P=0.0001;
Pinteraction<0.0001). There were no between-group differences in change in
Kansas City Cardiomyopathy Questionnaire overall summary score during
follow-up in all patients or in those with reduced or preserved LVEF.
<br/>CONCLUSION(S): Transcatheter interatrial shunt implantation was safe
but did not improve outcomes in patients with HF. However, the results
from a prespecified exploratory analysis in stratified randomized groups
suggest that shunt implantation is beneficial in patients with reduced
LVEF and harmful in patients with preserved LVEF. REGISTRATION: URL:
https://www.clinicaltrials.gov; Unique identifier: NCT03499236.

<54>
Accession Number
2034677700
Title
The effects of exercise-based prehabilitation in patients undergoing
coronary artery bypass grafting surgery: A systematic review of randomized
controlled trials.
Source
Heart and Lung. 69 (pp 41-50), 2025. Date of Publication: 01 Jan 2025.
Author
Yamikan H.; Ahiskali G.N.; Demirel A.; Kutukcu E.C.
Institution
(Yamikan, Ahiskali, Demirel, Kutukcu) Hacettepe University, Faculty
Physical Therapy and Rehabilitation, Ankara, Samanpazari 06100, Turkey
Publisher
Elsevier Inc.
Abstract
Background: Postoperative exercise-based rehabilitation improves the
physical performance and health-related outcomes of patients undergoing
coronary artery bypass grafting (CABG). However, the effectiveness of
exercise-based prehabilitation in patients undergoing CABG remains
unknown. <br/>Objective(s): The purpose of this systematic review was to
investigate the effects of exercise-based prehabilitation on functional
exercise capacity, postoperative complications, anxiety, depression,
self-efficacy, quality of life, length of hospital and intensive care unit
stay, frailty, and endothelial function in patients undergoing CABG
surgery. <br/>Method(s): This systematic review followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. The study protocol is recorded in the PROSPERO database
(registration number CRD42023488530). PubMed, the Physiotherapy Evidence
Database (PEDro), Google Scholar, Web of Science, Scopus, and the Cochrane
Library were searched from inception to December 2023. The titles and
abstracts of the studies were screened using Rayyan Ai software. After
full-text screening, randomized controlled trials that met the inclusion
criteria were included. <br/>Result(s): Five randomized controlled trials
involving 616 participants were included. The systematic review suggests
strong evidence that exercise-based prehabilitation improved functional
capacity and moderate evidence that it reduced postoperative complications
and length of hospital stay. Although there was conflicting evidence
regarding the effects of exercise-based prehabilitation on quality of
life, there was limited evidence of its effects on physical activity,
anxiety, depression, self-efficacy, frailty, and endothelial function.
<br/>Conclusion(s): Exercise-based prehabilitation can be recommended for
improvements in functional capacity, postoperative complications, and
length of hospital stay in patients undergoing CABG.<br/>Copyright &#xa9;
2024 Elsevier Inc.

<55>
Accession Number
2034707801
Title
Effect of impaired kidney function on outcomes and treatment effects of
oral anticoagulant regimes in patients with atrial fibrillation in a
real-world registry.
Source
PLoS ONE. 19(9) (no pagination), 2024. Article Number: e0310838. Date of
Publication: September 2024.
Author
Salbach C.; Milles B.R.; Hund H.; Biener M.; Mueller-Hennessen M.; Frey
N.; Katus H.; Giannitsis E.; Yildirim M.
Institution
(Salbach, Milles, Hund, Biener, Mueller-Hennessen, Frey, Katus,
Giannitsis, Yildirim) Department of Internal Medicine III, Cardiology,
University Hospital of Heidelberg, Heidelberg, Germany
Publisher
Public Library of Science
Abstract
Background The impact of impaired kidney function on outcomes and
treatment benefits of vitamin-K antagonists (VKA) versus direct oral
anticoagulants (DOAC) in patients with atrial fibrillation (AF) has
insufficiently been investigated in randomized controlled studies (RCTs).
Most studies and registries are either biased due to incomplete enrolment
of consecutive patients in large pharma industry sponsored registries, or
due to short recruitment periods or incomplete assessment of important
variables in national registries. Methods This study uses data from the
Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective
single-center registry of 10,222 consecutive patients with AF presenting
to the emergency department of University Hospital of Heidelberg from June
2009 until March 2020. Rates of all-cause mortality, stroke, major
bleeding and myocardial infarction (MI) were related to the presence and
severity of impaired presenting kidney function, as well as to assigned
treatment with VKA vs. DOAC. Results The risks for all-cause mortality
(HR: 3.26, p<0.001), stroke (HR: 1.58, p<0.001), major bleeding (HR: 2.28,
p<0.001) and MI (HR: 2.48, p<0.001) were significantly higher in patients
with an eGFR<60 ml/min at admission and increased with decreasing eGFR.
After adjustment for variables of CHA<inf>2</inf>DS<inf>2</inf>VASc-score,
presence of eGFR <60 ml/min remained as an independent predictor for
all-cause mortality, major bleeding and MI. The hazard ratio (HR) for
all-cause mortality, major bleedings and MI was significantly lower in
patients receiving DOAC compared to VKA. Conclusion Findings from our
large real-life registry confirm the data from RCTs and extend our
knowledge on the effectiveness and safety of DOACs to subjects that were
underrepresented in RCTs.<br/>Copyright &#xa9; 2024 Salbach et al. This is
an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are
credited.

<56>
Accession Number
2033296955
Title
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac
Allograft Vasculopathy in Heart Transplant Recipients.
Source
JACC: Heart Failure. 12(10) (pp 1677-1688), 2024. Date of Publication:
October 2024.
Author
Broch K.; Lemstrom K.B.; Gustafsson F.; Eiskjaer H.; Karason K.; Gjesdal
G.; Fagerland M.W.; Pentikainen M.; Lommi J.; Gude E.; Andreassen A.K.;
Clemmensen T.S.; Christiansen E.H.; Bjorkelund E.; Berg E.S.; Arora S.;
Gullestad L.
Institution
(Broch, Gude, Andreassen, Bjorkelund, Berg, Gullestad) Oslo University
Hospital Rikshospitalet, Oslo, Norway
(Broch, Gullestad) KG Jebsen Center for Cardiac Research, University of
Oslo, Oslo, Norway
(Lemstrom, Pentikainen, Lommi) Helsinki University Hospital Heart and Lung
Center and University of Helsinki, Helsinki, Finland
(Gustafsson) Rigshospitalet-Copenhagen University Hospital, Copenhagen,
Denmark
(Eiskjaer, Clemmensen, Christiansen) Aarhus University Hospital, Aarhus,
Denmark
(Karason) Transplant Institute, Sahlgrenska University Hospital and
Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
(Gjesdal) Cardiology Unit, Department of Clinical Sciences, Lund
University and Department of Heart and Lung Medicine, Skane University
Hospital, Lund, Sweden
(Fagerland) Oslo Center for Biostatistics and Epidemiology, Research
Support Services, Oslo University Hospital, Oslo, Norway
(Arora) Faculty of Medicine, University of Oslo, Oslo, Norway
Publisher
Elsevier Inc.
Abstract
Background: Cardiac allograft vasculopathy is characterized by increased
coronary intimal thickness and is a leading cause of death in heart
transplant (HTx) recipients despite the routine use of statins. The
experience with inhibitors of proprotein convertase subtilisin-kexin type
9 in HTx recipients is limited. Our hypothesis was that lowering
cholesterol with the proprotein convertase subtilisin-kexin type
9inhibitor evolocumab would reduce coronary intimal thickness in these
patients without compromising safety. <br/>Objective(s): This double
blind, randomized trial was conducted to test whether evolocumab reduces
the burden of cardiac allograft vasculopathy. <br/>Method(s): Patients who
had received a cardiac allograft at 1 of the Nordic transplant centers
within the prior 4 to 8 weeks were randomized to monthly subcutaneous
injections of evolocumab 420 mg or matching placebo. The primary endpoint
was the baseline-adjusted maximal intimal thickness as measured by
intracoronary ultrasound after 12 months' treatment. <br/>Result(s): The
trial enrolled 128 patients between June 2019 and May 2022. Matched pairs
of coronary ultrasound images were available for 56 patients assigned to
evolocumab and 54 patients assigned to placebo. At 12 months, the adjusted
mean difference in the maximal intimal thickness between the 2 arms was
0.017 mm (95% CI: -0.006 to 0.040; P = 0.14). The mean reduction in
low-density lipoprotein cholesterol with evolocumab compared with placebo
was 1.11 mmol/L (95% CI: 0.86-1.37 mmol/L). The use of evolocumab was not
associated with an increase in adverse events. <br/>Conclusion(s): Twelve
months of treatment with evolocumab substantially reduced low-density
lipoprotein cholesterol but did not reduce maximal coronary intimal
thickness in HTx recipients. (Cholesterol Lowering With EVOLocumab to
Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant
Recipients [EVOLVD]; NCT03734211)<br/>Copyright &#xa9; 2024 The Authors

<57>
Accession Number
2028810040
Title
Effect of topical application of autologous platelet gel on sternal wound
infection after cardiac surgery: A meta-analysis.
Source
International Wound Journal. 21(3) (no pagination), 2024. Article Number:
e14761. Date of Publication: March 2024.
Author
Li Y.; Wu Z.
Institution
(Li, Wu) Department of Cardiovascular Surgery, West China Hospital,
Sichuan University, Chengdu, China
Publisher
John Wiley and Sons Inc
Abstract
Following heart operation, a severe life-threatening complication has been
identified by investigators who have recently discovered that local
application of platelet-rich plasma (PRP) can lower the rate of wound
infection in heart surgery. Nevertheless, due to the low quality of these
trials, we have tried to perform high-quality meta-analyses to prove the
efficacy of PRP in heart surgery for post-operative wound infections. In
this study, five randomised controlled trials (RCTs) were chosen from
three databases, and there were 1005 studies to analyse the data. Among
181 cases, PRP was applied to the surgical site, and 205 in the control
group. Both the CI and the OR or the average difference (MD) were computed
with either a fixed or random-effect model. A meta-analysis of the data
was carried out with RevMan 5.3. The results showed that there were no
statistically significant differences in the incidence of post-operative
surgical site infection (SSI) in control group compared to those treated
with PRP gel (OR, 0.97; 95% CI, 0.38, 2.47; p = 0.95); In the heart
operation, the local application of PRP gel decreased the rate of drainage
after operation (MD, -217.82; 95% CI, -335.38, -100.26; p = 0.0003); The
operation time of the PRP gel was not significantly different from that of
the control group (MD, 12.65; 95% CI, -2.95, 28.24; p = 0.11). Contrary to
earlier research, the application of autoplatelet gel in heart surgery did
not seem to decrease operative site infections after the operation, but it
did decrease the amount of postoperative drainage. Nevertheless, because
of the limited number of RCTs in this meta-analysis, caution should be
exercised in their treatment. More high-quality randomised, large-sample
trials are required to further confirm the findings.<br/>Copyright &#xa9;
2024 The Authors. International Wound Journal published by
Medicalhelplines.com Inc and John Wiley & Sons Ltd.

<58>
Accession Number
2027212261
Title
Transcatheter left atrial appendage occlusion in patients with chronic
kidney disease: a systematic review and meta-analysis.
Source
Clinical Research in Cardiology. 113(10) (pp 1485-1500), 2024. Date of
Publication: October 2024.
Author
Flores-Umanzor E.; Asghar A.; Cepas-Guillen P.L.; Farrell A.; Keshvara R.;
Alvarez-Rodriguez L.; Osten M.; Freixa X.; Horlick E.; Abrahamyan L.
Institution
(Flores-Umanzor, Keshvara, Alvarez-Rodriguez, Osten, Horlick) Toronto
Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre,
University Health Network, Toronto, ON, Canada
(Asghar, Abrahamyan) Toronto General Hospital Research Institute,
University Health Network, 10th Floor Eaton North, Room 237, 200 Elizabeth
Street, Toronto, ON M5G 2C4, Canada
(Asghar, Abrahamyan) Institute for Health Policy, Management, and
Evaluation, University of Toronto, Toronto, ON, Canada
(Cepas-Guillen, Freixa) Cardiology Department, Cardiovascular Institute,
Hospital Clinic, University of Barcelona, Barcelona, Spain
(Farrell) Library and Information Services, University Health Network,
Toronto, ON, Canada
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Chronic kidney disease (CKD) is a risk factor for embolic
stroke, and many nonvalvular atrial fibrillation (NVAF) patients have
concomitant CKD. Anticoagulation therapy can be challenging in CKD due to
increased bleeding risk, and left atrial appendage occlusion (LAAO) may be
a promising alternative. <br/>Objective(s): This systematic review aimed
to consolidate current evidence on the safety and effectiveness of
transcatheter LAAO in patients with CKD and end-stage renal disease
(ESRD). <br/>Method(s): Medline, Cochrane, and Embase databases were
searched from inception to September 2, 2022. We conducted a meta-analysis
if an outcome was evaluated in at least two similar studies.
<br/>Result(s): We included 15 studies with 77,780 total patients. Of the
15 studies, 11 had a cohort design (five prospective and six
retrospective), and four were case series. Patients with CKD were older
and had a higher prevalence of comorbidities than non-CKD patients. The
two groups did not differ in procedural failure rate, vascular
complications, or pericardial tamponade. CKD patients exhibited higher
odds of in-hospital acute kidney injury (AKI) and bleeding, longer-term
bleeding, and mortality than those without CKD. The risk of in-hospital
and longer-term cardioembolic events was similar between CKD and non-CKD
populations (odds ratio = 1.01 [95% CI 0.70-1.15] and 1.05 [95% CI
0.55-2.00], respectively). Patients with ESRD had higher odds of
in-hospital mortality and cardioembolic events than non-ESRD patients,
with no differences in risk of pericardial tamponade. <br/>Conclusion(s):
Based on observational studies, LAAO may be an effective option to prevent
cardioembolic events in CKD. However, CKD patients may have higher odds of
AKI and in-hospital and long-term bleeding and mortality. The adverse
clinical outcomes observed in CKD patients may be attributed to this
population's high burden of comorbidities, especially among those with
ERSD, rather than the LAAO procedure itself. To ensure maximum clinical
benefit, careful patient selection, management, and surveillance involving
multidisciplinary teams are essential for CKD patients undergoing LAAO.
Graphical abstract: Transcatheter Left Atrial Appendage Occlusion (laao)
Can Prevent Cardioembolic Events In Chronic Kidney Disease (ckd) Patients.
However, Ckd Patients, Particularly Those With End-stage Renal
Disease/dialysis (esrd), May Face Increased Odds Of Acute Kidney Injury,
In-hospital And Long-term Bleeding, And Mortality. Notably, These Adverse
Outcomes In Ckd Patients May Be Linked To Their High Comorbidity Burden,
Particularly In Those With Esrd, Rather Than The Laao Procedure Itself.
Careful Patient Selection, Management, And Surveillance Involving
Multidisciplinary Teams Are Essential For Ckd Patients Undergoing Laao To
Ensure Maximum Clinical Benefit Transcatheter left atrial appendage
occlusion (LAAO) can prevent cardioembolic events in chronic kidney
disease (CKD) patients. However, CKD patients, particularly those with
end-stage renal disease/dialysis (ESRD), may face increased odds of acute
kidney injury, in-hospital and long-term bleeding, and mortality. Notably,
these adverse outcomes in CKD patients may be linked to their high
comorbidity burden, particularly in those with ESRD, rather than the LAAO
procedure itself. Careful patient selection, management, and surveillance
involving multidisciplinary teams are essential for CKD patients
undergoing LAAO to ensure maximum clinical benefit. (Figure
presented.)<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer-Verlag GmbH Germany 2023.

<59>
Accession Number
2031513807
Title
Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary
stents vs. everolimus-eluting bioresorbable vascular scaffolds-insights
from the EVERBIO-2 trial.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1426348. Date of Publication: 2024.
Author
Bengueddache S.; Cook M.; Lehmann S.; Arroyo D.; Togni M.; Puricel S.;
Cook S.
Institution
(Bengueddache, Cook, Lehmann, Arroyo, Togni, Puricel, Cook) Department of
Cardiology, Fribourg University and Hospital, Fribourg, Switzerland
Publisher
Frontiers Media SA
Abstract
Background: Bioresorbable vascular scaffolds (BVSs) have been developed as
a potential solution to mitigate late complications associated with
drug-eluting metallic stents (DESs) in percutaneous coronary intervention
for coronary artery disease. While numerous studies have compared BVSs to
DESs, none have assessed clinical outcomes beyond 5 years.
<br/>Objective(s): This study aimed to compare the 10-year clinical
outcomes of patients treated with BVSs vs. DESs. <br/>Method(s): The
EverBio-2 trial (Comparison of Everolimus- and Biolimus-Eluting Coronary
Stents with Everolimus-Eluting Bioresorbable Vascular Scaffold) is a
single-center, assessor-blinded, randomized controlled trial that enrolled
240 patients allocated in a 1:1:1 ratio to receive BVSs,
everolimus-eluting stents, or biolimus-eluting stents (BESs). Clinical
follow-up was scheduled for 10 years. <br/>Result(s): Clinical follow-up
was completed in 222 patients (93%) at the 10-year mark. The rate of
device-oriented composite events (DOCE) was 28% in the DES group and 29%
in the BVS group (p = 0.72) at 10 years. Similarly, the rate of
patient-oriented composite events (POCE) was 55% in the DES group and 49%
in the BVS group (p = 0.43) at 10 years. Notably, the rate of myocardial
infarction (MI) within the target vessel was 5% in the BVS group and 0% in
the BES group (p = 0.04), while the rate of any MI was 10% in the BVS
group and 2% in the BES group (p = 0.04). In addition, the rate of
Academic Research Consortium (ARC) possible stent thrombosis was 3% in the
BVS group and 0% in the DES group (p = 0.04). <br/>Conclusion(s): Over 10
years, the rates of clinical DOCE and POCE were similar between the BVS
and DES groups but individual outcomes of stent thrombosis were higher
(3%) in the BVS group compared to the DES group. Clinical Trial
Registration: ClinicalTrials.gov, identifier (NCT01711931).<br/>Copyright
2024 Bengueddache, Cook, Lehmann, Arroyo, Togni, Puricel and Cook.

<60>
Accession Number
2031513622
Title
Unlocking the potential of deferoxamine: a systematic review on its
efficacy and safety in alleviating myocardial ischemia-reperfusion injury
in adult patients following cardiopulmonary bypass compared to standard
care.
Source
Therapeutic Advances in Cardiovascular Disease. 18 (no pagination), 2024.
Date of Publication: January-December 2024.
Author
Lamichhane A.; Sharma S.; Bastola B.; Chhusyabaga B.; Shrestha N.; Poudel
P.
Institution
(Lamichhane) College of Medical Sciences, Bharatpur 44200, Nepal
(Sharma, Bastola, Chhusyabaga, Shrestha, Poudel) College of Medical
Sciences, Bharatpur, Nepal
Publisher
SAGE Publications Ltd
Abstract
Background: Reperfusion injury, characterized by oxidative stress and
inflammation, poses a significant challenge in cardiac surgery with
cardiopulmonary bypass (CPB). Deferoxamine, an iron-chelating compound,
has shown promise in mitigating reperfusion injury by inhibiting
iron-dependent lipid peroxidation and reactive oxygen species (ROS)
production. <br/>Objective(s): The objective of our study was to analyze
and evaluate both the efficacy and safety of a new and promising
intervention, that is, deferoxamine for ischemia-reperfusion injury (I/R).
<br/>Design(s): Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines are used to perform the study. Data
sources and methods: We conducted a systematic review following PRISMA
guidelines to assess the efficacy and safety of deferoxamine in reducing
I/R injury following CPB. A comprehensive search of electronic databases,
namely, PubMed, Scopus, and Embase, yielded relevant studies published
until August 18, 2023. Included studies evaluated ROS production, lipid
peroxidation, cardiac performance, and morbidity outcomes. <br/>Result(s):
(a) ROS production: Multiple studies demonstrated a statistically
significant decrease in ROS production in patients treated with
deferoxamine, highlighting its potential to reduce oxidative stress. (b)
Lipid peroxidation: Deferoxamine was associated with decreased lipid
peroxidation levels, indicating its ability to protect cardiac tissue from
oxidative damage during CPB. (c) Cardiac performance: Some studies
reported improvements in left ventricular ejection fraction and wall
motion score index with deferoxamine. <br/>Conclusion(s): Our review shows
that deferoxamine is an efficacious and safe drug that can be used to
prevent myocardial I/R injury following CPB. It also highlights the need
for trials on a larger scale to develop potential strategies and
guidelines on the use of deferoxamine for I/R injury.<br/>Copyright &#xa9;
The Author(s), 2024.

<61>
Accession Number
2029865209
Title
Response to the comments on: The effect of low preoperative albumin on
long-term mortality: a meta-regression.
Source
Surgery Today. 54(10) (pp 1277-1278), 2024. Date of Publication: October
2024.
Author
Xu R.; Zhang W.
Institution
(Xu, Zhang) Department of Thoracic Surgery, The Second Affiliated
Hospital, Jiangxi Medical College, Nanchang University, 1 Minde Road,
Nanchang 330006, China
(Xu) Jiangxi Medical College, Nanchang University, Nanchang 330006, China
(Xu) Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun
Yat-Sen University, No. 52 Meihua East Road, Guangdong Province, Zhuhai
519000, China
Publisher
Springer

<62>
Accession Number
2031523178
Title
Assessing the cost-effectiveness of replacing antimetabolites with mTOR
inhibitors in heart transplant immunosuppression in China: a network
meta-analysis-based economic evaluation.
Source
International Journal of Clinical Pharmacy. (no pagination), 2024. Date
of Publication: 2024.
Author
Gu Y.; Liu B.; Lin X.; Chen J.; Chen X.; Jiang Y.; Zhu Y.; Li X.; Lou S.;
Zhu J.
Institution
(Gu, Liu, Lin, Chen, Lou, Zhu) Department of Pharmacy, Nanjing First
Hospital, China Pharmaceutical University, Nanjing 210006, China
(Gu, Liu, Lin, Chen, Lou, Zhu) Department of Pharmacy, Nanjing First
Hospital, Nanjing Hospital Afiliated to Nanjing Medical University,
Nanjing 210006, China
(Chen, Jiang, Zhu) Department of Cardiothoracic Surgery, Nanjing First
Hospital, Nanjing Hospital Affiliated to Nanjing Medical University,
Nanjing 210006, China
(Li) School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
(Li) Center for Global Health, School of Public Health, Nanjing Medical
University, Nanjing, China
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Although several pharmacoeconomic studies have assessed the
cost-effectiveness of maintenance immunosuppressive regimens for heart
transplant recipients, economic comparisons between various combination
drug therapies remain sparse. <br/>Aim(s): This study used an economic
evaluation based on network meta-analysis to assess the cost-effectiveness
of four immunosuppressive regimens for adult heart transplant recipients
in China. <br/>Method(s): We conducted a systematic search for clinical
trials in PubMed, Embase, Cochrane Library, Web of Science, China National
Knowledge Infrastructure (CNKI), Wanfang Data, and VIP database. A
validated Markov model was adapted to reflect the Chinese medical
landscape. Four maintenance immunosuppression regimens were considered:
tacrolimus/mycophenolate mofetil (TAC/MMF), cyclosporine/mycophenolate
mofetil (CSA/MMF), everolimus/cyclosporine (EVL/CSA), and
sirolimus/tacrolimus (SRL/TAC). The probabilities of health events were
derived from a comprehensive literature review. Direct medical costs,
adjusted for 2022 values, were from public documents and websites, while
utilities for quality-adjusted life-years (QALYs) were taken from previous
studies. Primary outcomes were mean lifetime cost, QALYs, and
cost-effectiveness, with a willingness-to-pay (WTP) threshold set at three
times China's GDP per capita in 2022. Sensitivity analyses were conducted
to test the robustness of the results. <br/>Result(s): The base case
analysis identified TAC/MMF as the most cost-effective regimen, producing
a mean of 6.31 QALYs per patient at a cost of Chinese Yuan (CNY)
534,182.89. Sensitivity analyses consistently reinforced TAC/MMF as the
most cost-effective and robust choice. <br/>Conclusion(s): TAC/MMF is the
most cost-effective maintenance immunosuppressive regimen for heart
transplant recipients within the Chinese health system. The study findings
are reinforced by sensitivity analyses, affirming their robustness amid
various uncertainties.<br/>Copyright &#xa9; The Author(s), under exclusive
licence to Springer Nature Switzerland AG 2024.

<63>
Accession Number
2034671077
Title
Management of atrial fibrillation in older adults.
Source
BMJ. (no pagination), 2024. Article Number: e076246. Date of Publication:
2024.
Author
Parks A.L.; Frankel D.S.; Kim D.H.; Ko D.; Kramer D.B.; Lydston M.; Fang
M.C.; Shah S.J.
Institution
(Parks) University of Utah, Division of Hematology and Hematologic
Malignancies, Salt Lake City, UT, United States
(Frankel) Cardiovascular Division, Perelman School of Medicine, The
University of Pennsylvania, Philadelphia, PA, United States
(Kim, Ko) Hinda and Arthur Marcus Institute for Aging Research, Hebrew
SeniorLife, Harvard Medical School, Boston, MA, United States
(Ko) Richard A and Susan F Smith Center for Outcomes Research, Beth Israel
Deaconess Medical Center, Boston, MA, United States
(Ko) Boston Medical Center, Section of Cardiovascular Medicine, Boston,
MA, United States
(Kramer) Richard A and Susan F Smith Center for Outcomes Research, Beth
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA,
United States
(Lydston) Massachusetts General Hospital, Treadwell Virtual Library,
Boston, MA, United States
(Fang) University of California, San Francisco, Division of Hospital
Medicine, San Francisco, CA, United States
(Shah) Massachusetts General Hospital, Division of General Internal
Medicine, Center for Aging and Serious Illness, Harvard Medical School,
Boston, MA, United States
Publisher
BMJ Publishing Group
Abstract
Most people with atrial fibrillation are older adults, in whom atrial
fibrillation co-occurs with other chronic conditions, polypharmacy, and
geriatric syndromes such as frailty. Yet most randomized controlled trials
and expert guidelines use an age agnostic approach. Given the
heterogeneity of aging, these data may not be universally applicable
across the spectrum of older adults. This review synthesizes the available
evidence and applies rigorous principles of aging science. After
contextualizing the burden of comorbidities and geriatric syndromes in
people with atrial fibrillation, it applies an aging focused approach to
the pillars of atrial fibrillation management, describing screening for
atrial fibrillation, lifestyle interventions, symptoms and complications,
rate and rhythm control, coexisting heart failure, anticoagulation
therapy, and left atrial appendage occlusion devices. Throughout, a
framework is suggested that prioritizes patients' goals and applies
existing evidence to all older adults, whether atrial fibrillation is
their sole condition, one among many, or a bystander at the end of life.
<br/>Copyright &#xa9; Published by the BMJ Publishing Group Limited.